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ABSTRACT 
 
The botulinum neurotoxins (BoNTs) and tetanus neurotoxin 
(TeNT) make up the clostridial neurotoxin (CNT) family. The CNTs are 
produced by Clostridium botulinum and Clostridum tetani respectively, 
and are the most potent human protein toxins. Eight CNT family 
members have been identified: seven botulinum neurotoxins (A-G) 
and tetanus neurotoxin (TeNT).  Intoxication with BoNT is largely 
restricted to peripheral motor neurons, and results in flaccid paralysis. 
TeNT is sorted into a retrograde axonal trafficking pathway, 
transported to the central nervous system, and causes spastic 
paralysis.  
 The CNTs are typical AB toxins. They are secreted as ~150 kDa 
single chain proteins that undergo processing to produce a disulfide 
linked, dichain active form. The “A” or active domain is ~50 kDa zinc 
dependent protease, also known as the light chain (LC), that inhibits 
synaptic vesicle fusion with the plasma membrane through cleavage of 
soluble N-ethylmaleimide sensitive factor attachment protein receptor 
(SNARE) proteins. LCs cleave one of three neuronal SNARE proteins, 
preventing synaptic vesicle exocytosis. The “B” subunit is ~100 kDa, 
and contains a heavy chain translocation domain (HCT) and heavy 
chain receptor binding domain (HCR). Through an unclear mechanism, 
 xiv 
 
the HCT undergoes a conformational change upon acidification and 
forms pH dependent channels, facilitating transport of the LC into the 
neuronal cytosol.  
 The HCR binds neuronal receptors on the presynaptic membrane 
of α-motor neurons. In order to explain the neuronal specificity of the 
CNTs, a dual receptor model was put forward. One co-receptor is 
ganglioside, a glycosphingolipid with a carbohydrate backbone 
decorated with sialic acids and a sphingolipid anchor. To satisfy the co-
receptor model, the CNTs bind either a resident synaptic vesicle 
protein or a second ganglioside.  
 The focus of this work was to examine mechanisms of CNT 
binding and translocation to better understand CNT pathogenesis.  
Special emphasis was placed on understanding the ganglioside binding 
interactions in retrograde axonal trafficking, BoNT/A1 and A2 subtype 
specific ganglioside interactions, and the role of receptor contributions 
in CNT translocation.   
 Improving our understanding of basic mechanisms of CNT 
pathogenesis, including binding, entry, and translocation we can 
improve inhibitor designs, vaccine development, and further CNT 
platforms for pharmaceutical development. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Clostridial toxins 
 Bacteria have had a broad impact on humanity and affect our 
lives in both positive and negative ways. One genus, Clostridium, has 
significantly impacted the health of many animals including humans. 
Clostridia are primarily environmental, anaerobic spore-forming 
bacteria capable of using almost unlimited nutrient sources [1]. Of the 
~150 known clostridial species, 10% are pathogenic and produce 
about 20% of known bacterial toxins [2]. Of particular relevance to 
humans are Clostridium perfringens and Clostridium sordellii which 
produce multiple toxins including hemolysin, collagenase, fibrinolysin, 
and β-pore forming, cholesterol dependent cytolysins that contribute 
to the condition of Clostidia gas gangrene in humans and animals and 
have caused numerouse deaths world-wide [3, 4]. Other species of 
note are: Clostridium difficile which produces large glucosylating toxins 
[5]; Clostridium tetani that produces tetanus neurotoxin (TeNT); and 
Clostridium botulinum, C. baratii, C. argentinense, and C. butyricum 
that produce botulinum neurotoxins (BoNTs). Together, BoNTs and 
TeNT are known as the clostridial neurotoxins (CNTs) (Table 1).  
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Table 1. Principal diseases of toxigenic clostridia 
 
Table 1.       
Phylogenetic heterogeneity, number of toxins, and subsequent main 
diseases of toxigenic Clostridium species. 
Clostridium 
species Toxin number  Main disease   
C. argentinense 1  Botulism    
C. baratii 2  Botulism    
C. botulinum 3  Botulism    
C. butyricum 1  Botulism    
C. bifermentans 3  Gangrene   
C. chauvoei 4  Gangrene   
C. difficile 3  Colitis    
C. haemolyticum 3  Hemoglobinuria   
C. histolyticum 5  Gangrene   
C. novyi 8  Gangrene   
C. perfringens 14  Gangrene, enteritis  
C. septicum 4  Gangrene, enterotoxemia 
C. sordellii 4  Gangrene   
C. spiroforme 1  Enteritis    
C. tetani 2  Tetanus    
 
Reprinted from Popoff, M., Bouvet, P. Genetic characteristics of toxigenic Clostridia 
and toxin gene evolution. Toxicon. Volume 75; 1 December 2013, Pages 63–89 with 
permission from Elsevier. 
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They are neuro specific with an estimated LD50 of 1-3ng/kg, and 
considered the most lethal proteins known to man [2]. TeNT, a protein 
neurotoxin, is the causative agent of tetanus, a disease diagnosed by 
general rigidity and convulsive spasms, first described by Hippocrates 
in the 5th century BC In 1884 Carle and Rattone successfully 
transmitted tetanus to animals through infected human pus [6]. Follow 
up experiments identified tetanus neurotoxin (TeNT), as the causative 
agent of tetanus. The closely related botulinum neurotoxins (BoNTs) 
and TeNT comprise the clostridial neurotoxin (CNT) family. CNTs are 
considered the most potent naturally produced protein toxins. An 
estimated lethal dose of BoNT/A for humans is ~1ng/kg [7]. 
 
1.2 Clostridial neurotoxins 
 The clostridial neurotoxin (CNT) family includes eight family 
members: seven serotypes of botulinum neurotoxin (BoNTs A-G) and 
tetanus neurotoxin [8, 9]. Intoxication with TeNT occurs occasionally 
as a complication of deep wound infections with Clostridium tetani. 
Infection is initiated by contamination of open wounds or abrasions in 
the skin with endospores, commonly found in the soil environment. 
Upon germination, vegetative cells rapidly replicate within the tissue 
releasing enzymes and exotoxins including TeNT into the lymph and 
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blood system. The toxin is then transported to the neuromuscular 
junctions where intoxication occurs. 
 Botulism, the condition that results from intoxication with BoNT, 
was recognized in the 1820s with the onset of industrial scale 
manufacturing of foods after routinely causing food poisoning in 
sausages or “botulus” [10]. There are six phylogenetically distinct 
groups of clostridia that produce seven antigenically distinct BoNTs: 
Clostridium botulinum (group I-III); Clostridium argentinense; 
Clostridium butyricum; and Clostridium baratii (Table 2) [11-14]. 
Seven BoNT serotypes are identified by letter (A-G), where antiserum 
specific for one BoNT serotype cannot neutralize intoxication by a 
different serotype. In general, genes encoding BoNTs A, B, E, and F 
are located on the bacterial chromosome, BoNT serotypes C and D are 
transcribed from bacteriophage, and BoNT G and TeNT are located on 
a plasmid [11]. The seven BoNT serotypes are further divided into 
subtypes if they vary by more than 2.5% amino acid identity [2, 15]. 
Humans are likely sensitive to all CNTs, but only a subset: BoNTs A, B, 
E, F, and TeNT have been associated with natural human intoxications 
[16]. The natural variation observed with the BoNTs has not been 
observed with TeNT [17].  
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Table 2: BoNT phylogeny 
 
Botulinum       
 Proteolytic 
C. botulinum 
Group I 
Non-Proteolytic 
C. botulinum 
Group II 
C. botulinum 
Group III 
C. argentinense C. 
butyricum 
C. 
baratii 
Serotype A, B, F B, E, F C, D G E F 
Subtype A1, A2, A3, 
A4, A5, B1, 
B2, B3, A(B) 
Ab, Ba, Bf, 
F1, F2, F3, 
F4, F5 
E1, E2, E3, E6, 
E7, E8 
No proteolytic 
B, F6 
C, D, C/D, 
D/C 
 E4, E5 F7 
 
 
Reprinted from Popoff, M., Bouvet, P. Genetic characteristics of toxigenic Clostridia 
and toxin gene evolution. Toxicon. Volume 75; 1 December 2013, Pages 63–89 with 
permission from Elsevier. 
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In 2014, data from the Centers for Disease Control and Prevention 
(CDC) indicated 9% of laboratory confirmed cases of botulism 
originated from foodborne contamination, 80% were associated with 
infant botulism, 10% were from a wound source, and 1% of cases 
were from an unknown origin 
(http://www.cdc.gov/nationalsurveillance/botulism-surveillance.html). 
Infant botulism is a unique condition that occurs when contaminated 
spores are ingested, transmitting BoNT from the GI tract into the 
bloodstream [18, 19]. Specifically, spores that have been introduced 
into the body and survive the low pH environment of the stomach are 
able to germinate in the anaerobic environment of the gut. Once in the 
gut, toxin transcytoses the intestinal barrier and enters general 
circulation. In vitro data supports the role of CNT transcytosis. 
However, efficiency varies with serotype [20, 21]. Although not 
represented in the CDC study, aerosol delivery of BoNTs results in 
botulism, as detected in animal models. These data suggest 
developing weaponized BoNTs are possible [22, 23].  
 
1.2.1 Disruption of neuronal signaling 
 BoNT and TeNT have similar mechanisms of pathogenesis. BoNT 
is largely retained in the peripheral nervous system, preventing the 
release of acetylcholine, resulting in flaccid muscle paralysis. TeNT 
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undergoes retrograde axonal trafficking to reach the central nervous 
system where it prevents the release of inhibitory neurotransmitters 
such as γ-aminobutyric acid (GABA) and glycine, causing spastic 
muscle paralysis [24, 25]. In either case, patients usually die from 
asphyxiation, as the muscles that control breathing become paralyzed. 
 The CNTs are typical AB toxins and share common structural 
organization [24, 26]. They are initially synthesized as ~150 kDa 
single-chain molecules that must undergo proteolytic cleavage in order 
to convert to active di-chain molecules. CNTs are composed of an N-
terminal zinc metalloprotease domain (~50 kDa) termed light chain 
and a C-terminal domain (~100 kDa) termed heavy chain involved in 
neuronal entry linked through a single disulfide bond [9, 26, 27]. The 
light chain (LC, active, or protease domain) is specific for neuronal 
SNARE (soluble N-ethylmaleimide attachment protein receptor) 
proteins [28, 29]. The heavy chain (HC) has two functional domains: 
an N-terminal heavy chain translocation domain (HCT) and a C-
terminal heavy chain receptor binding domain (HCR) domain with sub-
domains HCRN and HCRC. 
 CNT intoxication is a three step process: binding and 
internalization, translocation, and cleavage of substrate. In step one, 
HCRs bind the presynaptic membrane of α-motor neurons via co-
receptor interactions. All CNTs bind gangliosides, complex 
 8 
 
glycosphingolipids decorated with one or more sialic acid sugars. A 
subset also bind synaptic vesicle proteins. With the exception of 
BoNT/C, BoNT/D, and mosaic toxins like BoNT C/D and D-SA, 
ganglioside binding occurs through a conserved ganglioside binding 
motif (GBM) [30, 31]. BoNT/C and /D lack the conserved GBM but still 
coordinate gangliosides for binding and entry [31]. 
After binding to motor neurons, BoNTs undergo receptor 
mediated endocytosis and uptake into acidified endosomal 
compartments. By comparison, TeNT is rapidly sorted into the 
retrograde axonal pathway for transport to the central nervous system 
(CNS) [9, 32]. The mechanism by which TeNT is delivered to the CNS 
is unclear. However, the heavy chain receptor binding domain of TeNT 
(HCR/T) has been shown to co-localize with Rab5 type endosomes 
prior to retrograde trafficking in Rab7 positive structures suggesting 
this is a dynamic process [33]. Once TeNT reaches the CNS, it is 
released from motor neurons to intoxicate inhibitory interneurons via a 
similar mechanism to the BoNTs. 
In step 2, the HCT presumably undergoes a structural change 
forming a protein conducting channel within the endosomal membrane 
facilitating LC translocation from the endosome lumen into the 
neuronal cytosol [8, 34, 35]. The thioredoxin/thioredoxin reductase-
redox system subsequently reduces the disulfide bond between HCT 
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and LC, releasing LC into the neuronal cytosol [36]. In step 3, LC 
cleaves one or more neuronal SNARE proteins preventing the 
formation of functional SNARE complexes, and thereby abrogating 
synaptic vesicle exocytosis [36]. 
 
1.3 Clostridial neurotoxin structure 
 The CNTs are extremely complex nanomachines that have 
developed high specificity for neuronal membranes and protein 
substrates. The CNTs share between 36.5% and 51.6% overall amino 
acid sequence identity and common structural characteristics [37]. 
However, individual domains within the CNTs typically contain higher 
amino acid sequence conservation as compared to overall amino acid 
identity [26, 37]. Crystal structures of BoNT/A (PDB: 3BTA, solved at 
3.3 Å), BoNT/B (PDB: 2NPO, solved at 2.6 Å) and BoNT/E (PDB: 3FFZ, 
solved at 2.6 Å) show similar trimodular domain organization. 
However, in the crystal structure of BoNT/E the LC and HCR domain 
were found on the same side of the HCT domain where as in BoNT/A, 
the HCT was between the LC and HCR (Figure 1) [27, 38, 39]. 
Aspects of CNT structure are important to CNT function. The CNTs 
contain a protease sensitive loop  
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Figure 1. Organization of the clostridial neurotoxins. Active CNTs are disulfide 
AB toxins that contain 3 domains. (A) The light chain (LC) is shown in red, the heavy 
chain translocation domain (HCT) is shown in green, and the heavy chain receptor 
binding domain (HCR) is shown in blue. (B) Crystal structures of BoNT/A (PDB: 
3BTA) and BoNT/E (PDB: 3FFZ) showing LC, HCT, and HCR in red, green, and blue 
respectively. 
  
A. 
B. 
Light Chain (LC) Translocation  
Domain (HCT) 
Receptor Binding  
Domain(HCR) 
S S - 
A B 
BoNT/E BoNT/A 
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located between the LC and HC, that is cleaved either by bacterial or 
host proteases, forming a di-chain active toxin [24, 40, 41]. The HCT 
domain is primarily alpha helical containing two large (~100 Å) alpha 
helices and several smaller alpha-helices linked by variable loop 
regions and a “belt” region that wraps around the LC [26, 27, 42, 43]. 
The HCT translocation belt wraps LC in a manner similar to how LC 
bind SNAREs, suggesting the belt may chaperone LCs while in the 
holotoxin complex. These data suggest the HCT belt may help prevent 
autocatalysis or off target activity [44, 45].  
 The HCR consists of an HCRN subdomain of unknown function 
that adopts a jelly roll fold and an HCRC subdomain that adopts a 
modified β-trefoil fold that facilitates toxin binding [27, 46]. 
Additionally, individual recombinant LC and HCR domains from all 
known CNT serotypes have been purified in Escherichia coli (E. coli), 
undergone X-ray structure determination, and found to retain relevant 
domain activity: LCs cleave substrate and HCRs bind receptors and 
enter neurons [31, 47-51]. 
 
1.3.1 Clostridial neurotoxin binding and entry 
 In 1986 Montecucco proposed a “dual receptor” model in which 
toxins necessarily bind ganglioside and protein co-receptors as an 
explanation for the high specificity of CNTs for α-motor neurons [52]. 
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In this model, gangliosides act as the point of initial contact with the 
neuronal membrane while the protein mediates toxin entry [52].  
Ganglioside binding is mediated through a shallow pocket located at 
the distal tip of the HCR domain that is formed by a conserved 
ganglioside binding motif (GBM) defined by E/D…H…SXWY…G [51]. 
Gangliosides involved in neurotoxin binding generally contain a GA1 
oligosaccharide core (Gal4-GalNAc3-Gal2-Glc1-Cer) to which one or 
more sialic acids (in humans specifically, N-acetylneuraminic acid) are 
bound [53]. A second receptor for many of the BoNTs has been 
identified as a synaptic vesicle resident protein, specifically: synaptic 
vesicle protein 2 for BoNTs A, D, E, and F [54-56]; and 
synaptotagmins I and II for BoNTs B and G [57-59]. Additional 
comments on binding and entry are continued in Chapter 2-
Introduction. 
 
1.3.2 Clostridial neurotoxin translocation 
 In order to access the neuronal cytosol, LCs must cross the 
endosomal membrane and the disulfide bond linking the HC and LC 
must be reduced. Two BoNT/A variants lacking the HCR domain were 
able to create ion conducting channels in Neuro2a membranes: LC-
HCT was able to create ion conducting channels at low pH while HCT 
alone formed channels in a pH independent manner [35, 60, 61]. 
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The effect of pH on the HCT is not entirely clear. Although pH was not 
required for channel formation, the HCT may have neutral and low pH 
states as discussed in this thesis. Far UV spectroscopy of isolated LC/A 
at pH 5.0 and 7.4 showed a correlation between decreased alpha 
helical content at pH 5.0 and an increase in the presence of channel 
and protease activities [34]. The role of HCR in translocation is not 
clear. The HCR has been proposed to restrict HCT from membrane 
insertion until HCT was within the acidified interior of the endosome 
[35, 43, 60]. One proposed model suggests HCR is an intramolecular 
chaperone for HCT, regulating when HCT can insert into the lipid 
membrane in order to create a channel in the lipid bilayer and allowing 
LC to translocate [35]. Accordingly, BoNT/A was able to form 15-20 Å 
diameter channels in lipid membranes at low pH [62]. 
 Many aspects of CNT translocation are not well understood. Work 
in this dissertation supports the idea that HCR contributes to, but is 
not required for, translocation [63, 64]. Similarly, the mechanism of 
HCT channel formation prior to productive LC translocation is not fully 
understood. Additional comments on CNT translocation can be found in 
Chapter 4 Tetanus neurotoxin utilizes two sequential membrane 
interactions for channel formation. 
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1.3.3 Clostridial neurotoxin protease domain 
 All CNT LCs are zinc metalloproteases characterized by a 
conserved zinc binding motif (HEXXH) and belong to peptidase family 
M4 of which Thermolysin is the representative enzyme [65, 66]. All 
LCs bind one zinc atom in the active site but BoNT/C coordinates an 
additional zinc atom that is believed to contribute to LC structure [24, 
67]. Individual LCs cleave one or more of three SNARE protein 
substrates: SNAP-25 (synaptosomal associated protein of 25 kDa), 
VAMP2 (vesicle associated membrane protein 2 also referred to 
synaptobrevin 2), or syntaxin 1 (Table 3). BoNTs A and E recognize 
unique sites on SNAP-25; BoNTs B, D, F, G, and TeNT cleave VAMP2; 
BoNT C is able to cleave both SNAP-25 and syntaxin 1 [9, 49, 50, 66, 
68-75]. Intracellular localization of LC also varies among the CNTs with 
LC/A localizing to the plasma membrane and the remaining LCs 
appearing to be cytosolic [76, 77]. The mechanism(s) by which LC/A 
localizes to the plasma membrane is not fully resolved, but the N-
terminal 8 amino acids of play an essential role [76].  
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Table 3: Tetanus and botulinum neurotoxins: substrate cleavage sites 
 
Toxin Substrate Peptide Bond Cleaved: P4-P3-P2-P1- 
P1’-P2’-P3’-P4’ 
BoNT/A SNAP-25 Glu-Ala-Asn-Gln197-Arg-Ala-Thr-Lys 
BoNT/B VAMP2 (synaptobrevin) Gly-Ala-Ser-Gln76-Phe-Glu-Thr-Ser 
BoNT/C SNAP-25 and 
 
Syntaxin 1 
Ala-Asn-Gln-Arg198-Ala-Thr-Lys-Met 
 
Asp-Thr-Lys-Lys254-Ala-Val-Lys-Phe 
BoNT/D VAMP2 Arg-Asp-Gln-Lys61-Leu-Ser-Glu-Leu 
BoNT/E SNAP-25 Gln-Ile-Asp-Arg180-Ile-Met-Glu-Lys 
BoNT/F VAMP2 Glu-Arg-Asp-Gln60-Lys-Leu-Ser-Glu 
BoNT/G VAMP2 Glu-Thr-Ser-Ala81-Ala-Lys-Leu-Lys 
TeNT VAMP2 Gly-Ala-Ser-Gln76-Phe-Glu-Thr-Ser 
 
Adapted with permission from Physiological Reviews. Schiavo,G., Matteoli,M., 
Montecucco,C.  Neurotoxins Affecting Neuroexocytosis. Physiological Reviews. 4 
January 2000 Vol. 80 no. 2, 717-766 © The American Physiological Society. 
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The interactions between individual LCs and their cognate SNARE 
protein targets has been extensively studied. Unlike other zinc 
proteases, CNTs recognize extended regions of their substrates for 
cleavage. In the case of BoNTs A and E, two sub-sites have been 
identified within SNAP-25 which contribute to substrate recognition. 
The recognition or active site (AS) region contains the site of cleavage. 
The binding (B) domain, contributes to substrate affinity [45, 78, 79], 
While LC/T and LC/B recognize and cleave VAMP2 at the same site, 
[66] the substrate recognition sequences between the two LCs are 
very different [80]. One result of this knowledge is a variant of LC/E 
capable of cleaving SNAP-23, not SNAP-25 [81]. Duration of disease 
has been correlated to stability of SNARE complexes. LC/A shortens 
SNAP-25 by nine amino acids. Shortened SNAP-25 peptides may be 
retained within SNARE complexes, contributing to extended disease 
state and longer synaptic blockade [44, 82]. In contrast, LC/E cleaves 
a 26 amino acid product from SNAP-25, releasing SNAP-25 into the 
cytosol and correlating to a shorter duration of synaptic blockade [83, 
84]. 
 
1.4 Treatment and vaccine strategies 
 If an individual comes in contact with BoNT or spores that have 
germinated and are expressing toxin, treatment options are limited. 
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Primary therapies consist of supportive respiratory care and early 
delivery of antitoxin therapy [85, 86]. Antitoxin therapy neutralizes 
serotype specific intoxication, but only neutralizes unbound toxin [87]. 
Treatment for TeNT intoxication can be more complicated. Constant 
spasms associated with tetanus require administration of paralytic 
drugs to control muscle spasms in addition to gastric tube feeding and 
tracheostomy for breathing assistance [88-90]. There has been a 
significant decline in total reported tetanus cases since the 
development of a tetanus toxoid vaccine in 1924 [91]. However, in 
areas without access to the vaccine, deaths can be high. Development 
of a botulism vaccine has been more difficult. Using an approach 
similar to the creation of the tetanus vaccine, formalin treated C. 
botulinum extracts were alum precipitated to increase purity [92] and 
tested for serotype specificity [93, 94]. Reaction to the initial toxoid 
injection was mild, but more than one injection resulted in systemic 
reactions [94]. Additional vaccine efforts included development of a 
pentavalent vaccine in 1976 that included BoNTs A, B, C, D, and E 
[95]. The pentavalent BoNT toxoid was ethanol precipitated after 
formalin inactivation, creating a better tolerated vaccine candidate. 
The pentavalent vaccine was discontinued in 2011 because of short 
half-life, poor supply, and poor efficacy [96]. Recent vaccine 
development has utilized recombinant technology. An HCR derived 
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vaccine candidate derived from all seven BoNT serotypes was found to 
be protective [97-99]. Full length, catalytic inactive vaccine candidates 
are also under investigation.  
 
1.5 Summary 
 TeNT and BoNT are highly potent neurotoxins. They are not 
cytotoxic, but, have exquisite specificity for the pre-synaptic neuronal 
membrane and have capacity to inhibit synaptic vesicle exocytosis. 
Outward disease presentation is the result of differences in the 
intracellular transport mechanisms of BoNTs and TeNT. Current 
research aims to understand fundamental aspects of CNT intoxication, 
shared and unique, among CNT members. This body of work focuses 
on understanding mechanisms of binding and entry and mechanisms 
of channel formation and translocation using TeNT and BoNT/A 
variants. 
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CHAPTER 2: INVESTIGATING THE ROLE OF GANGLIOSIDES 
IN RETROGRADE AXONAL TRANSPORT OF TETANUS 
NEUROTOXIN 
 
2.1 Abstract 
Botulinum neurotoxin (BoNTs) and tetanus neurotoxin (TeNT) together 
constitute the clostridial neurotoxin family (CNT). The CNTs are the 
most potent toxins known to man in part due to high specificity for the 
neuronal membrane and specific cleavage of SNARE proteins. The 
CNTs all bind at least one molecule of ganglioside to facilitate neuronal 
entry. Unlike the other CNT family members, TeNT is sorted into the 
retrograde axonal transport pathway after binding and entry. The 
mechanisms behind TeNT retrograde axonal trafficking are not 
completely understood. We propose a model whereby TeNT retrograde 
axonal trafficking is dependent on the unique ability to bind the 
ganglioside GM1a. Using structure-based mutagenesis in conjunction 
with a solid-phase ganglioside binding assay a TeNT variant, 
HCR/TARTS-ALoop, was created. Binding of HCR/TARTS-ALoop to GM1a was 
reduced by at least three orders of magnitude, while binding to 
gangliosides containing a Sia5 sugar was unaffected. Biochemical data 
suggested that replacement of threonine 1270 with a phenylalanine 
that is highly conserved among the BoNTs was critical for conferring 
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the dependence on the Sia5 sugar. Unexpectedly, restoration of the 
second ganglioside binding site in HCR/TARTS-ALoop, restored binding to 
ganglioside GM1a through an unknown mechanism. This novel protein 
variant, HCR/TMO, is able to bind and enter neuronal cells but appears 
to localize to unique microdomains within the plasma membrane.  
   
2.2 Introduction 
 CNTs (BoNTs A-G and TeNT) are considered the most lethal 
protein toxins known to man. Among the CNT serotypes, humans are 
more sensitive to BoNTs A, B, E, and F and TeNT than other serotypes 
[16]. The extreme potency of these toxins is due in part to high 
specificity for the neuromuscular junction and specificity to inhibit 
synaptic vesicle exocytosis through cleavage of “S”oluble “N”-
ethylmaleimide sensitive factor “A”ttachment protein “RE”ceptor 
(SNARE) substrate proteins [8, 9, 16]. CNT binding to the 
neuromuscular junction is a key first step in the intoxication process. A 
C-terminal receptor binding domain simultaneously recognizes 
synaptic vesicle proteins and complex glycosphingolipid, or more 
specifically ganglioside, co-receptors [100, 101]. Table 4 lists the 
current protein co-receptors identified for each BoNT serotype. [47, 
51, 102, 103].  
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Table 4. Tetanus and botulinum neurotoxin receptors 
Toxin type Protein receptor Non protein receptors 
BoNT/A SV2A, SV2B, SV2C Ganglioside 
BoNT/B Syt-I/II (synaptotagmin II) Ganglioside 
BoNT/C  Dual Ganglioside 
BoNT/D SV2 Ganglioside 
BoNT/E Glycosylated SV2A and B Ganglioside 
BoNT/F Glycosylated SV2 Ganglioside 
BoNT/G Syt-I/II (synaptotagmin II) Ganglioside 
TeNT SV2 and Nidogen* Dual Ganglioside 
 
SV2: synaptic vesicle protein 2, isoforms A-C; SytI/II: synaptotagmins I and II. 
*Multiple protein receptors have been proposed for TeNT. The most recent are SV2 
and Nidogen. Additional characterization is required to verify if these, or any other 
proposed protein receptors for TeNT play a biological role. 
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Although basic mechanisms of co-receptor recognition are understood, 
complex mechanisms of co-receptor recognition have not been 
completely characterized for all serotypes. In addition, the role of 
ganglioside co-receptor recognition in TeNT retrograde axonal 
trafficking is not understood. Complex gangliosides are located in the 
outer leaflet of the neuronal membrane and contain a common 
Ceramide-Glc1-Gal2-GalNAc3-Gal4 core (hereafter referred to as GA1) 
and at least one N- acetylneuraminic acid (sialic acid) creating “a” and 
“b” series gangliosides (Figure 2) [104-106]. A wealth of evidence 
supports the role of gangliosides as CNT co-receptors. For example, 
the binding affinity of BoNT/A for b series gangliosides was determined 
to be ~10-8 M and in the presence of a monoclonal antibody to 
ganglioside GT1b (Kd 0.33 nM), BoNT/A entry into neurons was less 
efficient [107]. Similarly, BoNT/A was insensitive to murine 
neuroblastoma (Neuro2A) cells chemically inhibited in ganglioside 
biosynthesis and to neurons from mice lacking both a and b series 
ganglioside synthase genes: β1,4-N-acetylgalactosaminyltransferase 
(GM2/GD2 synthase; EC 2.4.1.92) and α2,8 sialyltransferase (GD3 
synthase genes) [108-110]. 
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Figure 2. Ganglioside biosynthesis. Major gangliosides found in mammalian brain 
are in bold and annotated with an asterisk (*). GlcT: ceramide glucosyltransferase; 
GalT I/II: galactosyltransferase I/II; GalNAcT: N-acetylgalactosaminyltransferase; SAT 
I/II/III/IV: sialyltransferase I/II/III/IV. This research was originally published in The 
Journal of biological chemistry. Kolter, T, Proia, R. L, and Sandhoff, K.  Combinatorial 
ganglioside biosynthesis. J Biol Chem. 2002; 277: 29 :25859-62 © the American 
Society for Biochemistry and Molecular Biology and used with permission. 
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Together, these data suggest gangliosides are necessary for binding 
and entry of BoNT/A BoNTs A, B, E, and F and TeNT contain a 
conserved ganglioside binding motif (GBM) E/D…H…SXWY…G (Figure 
3) [47, 102, 111] which forms a shallow cleft in the surface of the HCR 
to which the oligosaccharide moiety of GA1 binds (Figure 4). The 
hydrophobic faces of the GalNac3-Gal4 sugars pack against the indole 
ring of the conserved tryptophan, whereas the polar faces are 
hydrogen bonded to the protein (Figure 4) [47, 51, 102, 112]. 
However, binding interactions with the GBM alone are not sufficient to 
bind ganglioside [47]. CNTs utilize non-conserved amino acids located 
outside the GBM to stabilize ganglioside binding (Figure 4). BoNTs A, 
B, E, and F stabilize the interaction between toxin and ganglioside by 
forming hydrogen bonds, in conjunction with additional hydrophobic 
interactions to a specific N-acetylneuraminic acid linked to Gal4 on the 
GA1 core (Figure 5) (indicated as Sia5). 
Unlike the BoNTs, binding of TeNT to gangliosides is not 
dependent on Sia5. TeNT stabilizes binding to gangliosides through a 
unique asparagine residue (N1219) that hydrogen bonds to GalNAc3 
(Figure 5) [47, 51, 102]. The interaction of N1219 with GalNAc3, 
rather than Sia5, confers upon TeNT the unique ability to bind 
gangliosides such as GM1a.  
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Figure 3. Structure based sequence alignment of BoNT and TeNT HCRs. 
Conserved amino acids in BoNT serotypes A,B,E, and F and TeNT HCRs are 
highlighted in yellow. Amino acids that form the conserved ganglioside binding motif 
(GBM) are highlighted in purple. This figure was originally published in The Journal of 
Biological Chemistry. Benson,M.A., Fu,Z., Kim J.J., Baldwin,M.R. Unique Ganglioside 
Recognition Strategies for Clostridial Neurotoxins. Journal of Biological Chemistry 
September 30, 2011; 286:34015-34022. © the American Society for Biochemistry 
and Molecular Biology and used with permission. 
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Figure 4. Structure of HCR/F in complex with GD1a- oligosaccharide (OS). 
(A) Ribbon representation of HCR/F (green) with GD1a-OS (atomic color sticks). (B) 
Ribbon representation illustrating position of GD1a-OS (atomic color sticks) in the 
HCR/F ganglioside binding motif (GBM). Amino acids that directly interact with GD1a-
OS shown as green sticks with hydrogen bond interactions. This figure was adapted 
from an original research article published in The Journal of Biological Chemistry. 
Benson,M.A., Fu,Z., Kim J.J., Baldwin,M.R. Unique Ganglioside Recognition Strategies 
for Clostridial Neurotoxins. Journal of Biological Chemistry September 30, 2011; 
286:34015-34022. © the American Society for Biochemistry and Molecular Biology 
and used with permission. 
 
  
A. B. 
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Fig 5. Model of HCR dependent ganglioside binding. Monosaccharides are 
represented by hexagons: Gal2 and Gal4 are colored white, GalNAc3 is colored light 
gray, and Sia5 is colored dark gray. Amino acids involved in binding to ganglioside 
are indicated by single letter codes. Hydrogen bonds are indicated by dashed lines. 
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Therefore, N1219 fulfills a function in TeNT analogous to the role of 
residues that hydrogen bond to Sia5 in the BoNTs.  
 Previous reports by Rummel et al. and Chen et al. established 
TeNT can simultaneously bind two gangliosides at physically separate 
binding sites [51, 102, 103, 111]. The conserved GBM forms the “W” 
site, so named because of the conserved tryptophan, W1289 in TeNT 
which interacts with the GA1 carbohydrate core. The second binding 
site (hereafter referred to as the “R” site) is centered around a unique 
arginine, R1226, which coordinates sialic acid moieties attached to the 
Gal2 sugar of the GA1 core [51]. The location of the R site in TeNT 
overlaps with the known protein co-receptor binding sites of BoNTs B 
and G suggesting it may play an important role in binding and entry 
[113]. This is supported by the observation that mutation of R1226 
abrogates ganglioside binding and results in an atoxic protein [114]. 
Importantly, mutation of R1226 does not impact ganglioside binding to 
the GA1 core, implying the two binding sites are functionally 
independent of one another [102]. Figure 6 validates the previously 
characterized variant HCR/TR1226L [102, 111]. In addition to a dual 
ganglioside model described for TeNT, co-receptor models describing 
TeNT binding to protein receptors have also been proposed [115, 116]. 
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Figure 6. HCR/T and HCR/TR1226L binding to GD1a and GM1a. (A) Binding of 
HCR/T (●) to immobilized GD1a or GM1a or HCR/TR1226L to 5 µg GD1a (▲) (left 
panel) or GM1a (▼) (right panel) to microtiter plates (B) Binding of HCR/TR1226L to 5 
µg GD1a (▲) or GM1a (▼). Experiments were performed in phosphate buffered 
saline with 1% BSA (w/v) and 0.04% (v/v) Tween-20 at 4ºC for 2hrs. Bound HCR 
complexes were detected by anti-FLAG M2 monoclonal antibody (1:10,000), goat 
anti-mouse poly HRP (1:12,000) and ultra TMB. The plates were read at 450 nM 
after quenching with 0.1M H2SO4. All values represent the arithmetic mean ± SD of 3 
independent experiments performed in triplicate. Data were plotted using GraphPad 
Prism version 5 (GraphPad Software Inc.). 
  
B. 
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Upon binding to the presynaptic membrane of α-motor neurons (MNs) 
BoNTs are rapidly internalized into acidifying compartments ultimately 
leading to SNARE protein cleavage and disruption of signal 
transmission. In contrast, TeNT is rapidly sorted into distinct vesicular 
carriers which undergo fast retrograde axonal transport to the spinal 
cord. Importantly, these vesicular compartments fail to acidify during 
transport, likely explaining the failure of TeNT to translocate the LC 
within MNs [117]. Upon reaching the dendritic bodies, TeNT is released 
into the adjacent synaptic clefts, allowing binding to the inhibitory 
interneurons present within the spinal column [32, 65]. TeNT is 
subsequently internalized into an acidified compartment resulting in 
the translocation of LC into the cytosol, where it cleaves the SNARE 
protein synaptobrevin-2, preventing release of the neurotransmitters 
γ-aminobutyric acid (GABA) and glycine [66]. The resultant reduction 
in the strength of inhibitory inputs on MNs results in a hyper-excited 
state, which in turn causes the characteristic violent and persistent 
spasms associated with tetanus. While the ability of TeNT to shuttle 
from the periphery to the central nervous system is universally 
accepted, the mechanistic basis for this process remains unknown. 
One proposed mechanism suggests after binding and entering 
MNs, TeNT is rapidly sorted to an alternate pathway to BoNTs where it 
co-localizes with p75NTR neurotrophin receptor and Tropomyosin 
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receptor kinase B (TrkB), facilitating retrograde axonal trafficking [33, 
118]. Additional data suggest that TeNT binding to the neuronal 
membrane can directly activate intracellular signaling cascades 
initiated by p75NTR neurotrophin receptor and Tropomyosin receptor 
kinase A (TrkA) among others [119], and that this may also contribute 
to the retrograde transport of TeNT. 
Interestingly, the unrelated alpha toxin from Clostridium 
perfringens also induces TrkA signaling, through a mechanism that is 
dependent on toxin binding to ganglioside GM1a [120]. This raises the 
possibility that TeNT binding to GM1a could be significant among the 
CNTs, as it may induce signaling required for productive retrograde 
axonal transport.  
In addition to the clostridial neurotoxins, ganglioside dependent 
retrograde trafficking is a mechanism of pathogenesis utilized by 
cholera toxin and the Escherichia coli (E. coli) heat labile family of 
toxins. Cholera toxin (CT) and the E. coli heat labile family of toxins 
(LT) utilize gangliosides as receptors and then undergo retrograde 
transport through the trans-Golgi network to the endoplasmic 
reticulum (ER). CT, LTI and LTIIc bind GM1a; LTIIa bind b series 
gangliosides such as GD1b, and LTIIb binds GD1a [121, 122]. In 
human intestinal epithelial cells, CT has been reported to bind GM1a 
and undergo retrograde transport. In similar experiments, LTIIb was 
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not able to undergo retrograde transport although it bound to the 
surface of human epithelial cells via GD1a receptor [122]. Later 
reports established the ceramide moiety of GM1a may play a 
significant role in the retrograde transport properties of GM1a and 
ultimately of CT bound to GM1a [123]. Recently, a beta lactamase 
reporter construct (βLac-LTIIc) was able to translocate β-lactamase 
when bound to b series gangliosides exogenously added to Neuro2a 
cells [124]. Together, these data suggest binding to specific 
gangliosides can lead to retrograde transport of expressed cargo 
protein. Additionally, these data suggest that the ability of TeNT to 
bind GM1a may be a necessary component in the ability of TeNT to 
undergo retrograde axonal trafficking. 
In the following study, we have investigated the potential role of 
ganglioside recognition in the retrograde transport of TeNT. Our model 
was: binding to ganglioside GM1a is required to sort TeNT into the 
retrograde axonal pathway. To test our model, we created a variant of 
TeNT that was dependent on the presence of the Sia5 sugar for 
binding and entry. In addition, we eliminated the dependence of GM1a 
in order to test the ability of TeNT to undergo GM1a dependent 
retrograde axonal trafficking. 
 
2.3 Experimental procedures 
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2.3.1 Site-directed mutagenesis of TeNT HCR 
 A previously described, modified, pET28a expression vector 
(Novagen) – hereafter referred to as pET28-3×FLAG – containing a 
3×FLAG epitope immediately downstream of the hexahistidine epitope 
tag was used as the expression vector for all TeNT HCR constructs 
[125]. E. coli optimized TeNT HCR DNA (aa 865-1315) was previously 
synthesized and subcloned into the modified pET28-3×FLAG 
expression vector via unique 5’ KpnI and 3’ PstI restriction sites [111]. 
Point mutations were introduced into the TeNT HCR gene by site 
directed mutagenesis using Quikchange® or Quikchange® II Site-
Directed Mutagenesis Kits (Agilent) and confirmed by DNA sequencing. 
See Appendix 6.1, Chapter 2 primers, for a complete list of 
primers used in this study. 
 
2.3.2 Generation of TeNT – BoNT HCR loop chimeras using 
Splicing by Overlap Extension (SOE)-PCR 
Chimeric HCR/T proteins containing short sequences of amino 
acids derived from BoNT A, E, or F were generated by Splicing by 
Overlap Extension (SOE)-PCR. For each PCR fragment, the primer at 
the end to be joined is constructed such that it has a 5’ overhang of 30 
nucleotides encoding BoNT amino acids which is complementary to the 
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5’ end of the second PCR fragment. In the first round of PCR, two 
fragments of approximately 1300 and 300 base pairs were amplified 
and subsequently gel purified. Once purified, a second round of PCR 
was carried out by mixing equimolar amounts of the two purified 
products with only primers from the two far ends. The overlapping 
complementary sequences introduced in round 1 served as primers 
and the two sequences containing the BoNT insertion were fused 
(Figure 7). DNA was digested using KpnI and PstI restriction 
enzymes, ligated into pET28-3×FLAG and verified by DNA sequencing. 
 
2.3.3 Expression and purification of wild-type and mutated 
TeNT HCRs 
 E. coli BL-21(DE3) was transformed with pET28-3×FLAG HCR 
and grown in Lysogeny broth (LB) in the presence of 50 µg/ml 
kanamycin (LBKan) at 37ºC overnight. Transformants were stored in 
12% (v/v) glycerol at -80ºC [125]. For purification of HCR, E. coli with 
pET28-3×FLAG HCR were plated onto LBKan agar plates and grown 
overnight at 37ºC. A single colony was isolated into 3 ml LBKan and 
grown for 3 hours at 37ºC.  
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Figure 7. Splicing by overlap extension PCR. Schematic of splicing by overlap 
PCR strategy. Unique PCR primers (#1 and #2) were designed to delete a segment 
of HCR/T DNA (E. coli optimized) and replace deleted DNA with similar sequence 
from BoNT A, E or F (E. coli optimized DNA). In step 2, PCR products from reactions 
#1 and #2 were used as PCR templates for step #3 to create TeNT-BoNT chimeras. 
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Subsequently, 250 µl of culture was spread onto fresh LBKan agar 
plates and grown overnight at 37ºC The lawn of bacteria was 
suspended in 8 ml LB and inoculated into 400 ml LBKan for 3 hours at 
37ºC at 250 r.p.m. (an OD600 of ~0.6). Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1 
mM. Incubation continued overnight following temperature reduction 
to 16ºC [111]. Bacterial cells were harvested by centrifugation at 5000 
×g for 20 min at 4ºC, lysed by French press, and clarified by 
centrifugation at 15000 ×g for 20 min at 4ºC. Lysates were filtered 
through a 0.22 µm cellulose acetate syringe type filter prior to 
sequential column chromatography: Ni2+-nitrilotriacetic acid (NTA) 
agarose (Qiagen) affinity chromatography followed by size exclusion 
chromatography using a S200-HR gel filtration column (GE 
Biosciences). Column fractions containing purified 3×FLAG-HCR were 
pooled, concentrated using an Amicon type centrifugal filtration device, 
and dialyzed into 500 mM NaCl 30 mM HEPES (pH 7.6) overnight at 
4ºC. Purified 3×FLAG-HCRs were stored undiluted at -80ºC. 
 
2.3.4 Solid phase ganglioside binding assay 
 A solid phase ganglioside binding assay was carried out as 
described previously [47]. Briefly, purified bovine brain gangliosides 
(GT1b, GD1b, GD1a, GM1a, GD3) (Matreya, LLC) were dissolved in 
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methanol (MeOH) at 2.5 or 5 mg/ml, diluted to 50 µg/ml in MeOH, and 
100 µl per well was applied to non-protein binding 96 well plates 
(Corning Costar #3591). MeOH was allowed to evaporate overnight at 
room temperature in order to immobilize the ganglioside onto the plate 
surface. Nonspecific binding sites were blocked by a 30 minute 
incubation in carbonate solution (50 mM Na2CO3 containing 2% BSA, 
pH 9.6). Various concentrations of HCRs were added to the plates and 
incubated at 4ºC for 90 minutes. Post incubation, 96 well plates were 
washed three times in PBS with 0.04% (v/v) Tween 20. 
 An antibody solution containing anti-FLAG M2 monoclonal 
antibody (1:10,000) and goat anti-mouse poly HRP (1:12,000; Pierce) 
in PBS with 1% BSA and 0.04% Tween20 was applied and incubated 
for 20 min at 4ºC. Following incubation, the plate was washed three 
times in PBS with 0.04% Tween 20. Bound HCR complexes were 
detected using Ultra TMB (Pierce) as the HRP substrate. The reaction 
was terminated by the addition of an equal volume of 0.1 M H2S04. 
The absorbance at 450 nm was determined using a plate reader 
(BioTek). Based on detection methodology it was not possible to 
directly determine the equilibrium dissociation constant (Kd). Rather, 
the concentration of HCR required to give 50% of maximum binding 
(B50) was estimated by fitting the data to a one-site binding model 
where 𝑌 = 𝐵max	∙ 𝑋 ∕ (B50+Χ)	using GraphPad Prism. The goodness of fit 
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was estimated by calculating R2, with values <0.9 indicating the model 
was not appropriate. 
 
2.3.5 Crystallization of HCR/TMO 
 HCR/TMO was crystallized by Zhuji Fu in the laboratory of Dr. 
Jung Ja Kim at the Medical College of Wisconsin. Purified HCR/TMO was 
purified by Joshua Burns (as described) dialyzed against 20 mM Tris-
HCl (pH 7.9) containing 100 mM NaCl and concentrated to a final 
concentration of 10 mg/ml. Crystals were obtained by vapor diffusion 
using hanging drop techniques. Hanging drops containing 2 µl of 10 
mg/ml HCR/TMO and 2 µl of well solution (100 mM bis(trispropane)) 
buffer, pH 7.0, 25% polyethylene glycol 2000 and 300 mM ammonium 
sulfate) were equilibrated against 0.5 ml of the well solution at 19°C. 
The HCR/TMO crystals belong to the triclinic space group P1, with cell 
dimensions a = 65.5, b = 84.3, and c = 117.6 Å and α = 72.6°, β = 
67.1°, and γ = 84.1°. There are four molecules in an asymmetric unit 
with a Matthews coefficient of 2.8 Å3/Da. The 2.4 Å data used in the 
initial molecular replacement were obtained at −175°C using an in-
house R-AXIS IV++ detector. HKL2000 [126] was used in the data 
processing.  The 1.9 Å data used for the later stages of refinement 
were collected at Advanced Photon Source beamline SBC 19ID. 
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Statistics for data collection and processing are summarized in Table 
5.The structure of HCR/TMO was solved by the molecular replacement 
method with MOLREP within the CCP4 program suite [127] in the 
resolution range of 20–4.0 Å. The monomer structure of HCR/T 
complexed with GT2 (Protein Data Bank code 3HMY) was used as the 
search model. The initial structure obtained from molecular 
replacement was refined using the program CNS [128]. The 
refinement protocol, as carried out by the Jung Ja Kim lab consisted of 
rigid body minimization, positional and temperature factor refinement, 
and simulated annealing. The structure was further refined with 
alternating manual adjustments using the TURBO-FRODO program 
package. The current model was completed with Rcrystal/Rfree values of 
0.212/0.243. The statistics of structural refinement are given in Table 
5. 
 
2.3.6 TeNT HCR binding to rat cortical neurons 
 12 mm acid etched coverslips were coated with 50 µg/mL poly-
D-lysine overnight. Coverslips were washed twice with cell culture 
grade water before neurons were plated. Rat embryonic day 18 (E18) 
cortical neurons (Brainbits) were disassociated per Brainbits protocol 
and cultured in Neurobasal medium supplemented with 0.5 mM  
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Table 5. Data collection and refinement statistics (molecular replacement) 
 HCR/TMO 
Data collection  
Space group P1 
Cell dimensions  
a, b, c (Å) 65.5, 84.3, 117.6 
α, β, γ  (°) 72.6, 67.1, 84.1 
Resolution (Å) 30-1.9 (1.97-1.90) * 
Rsym 0.059/0.409 
Ι / σΙ 16.2 (2.1) 
Completeness (%) 95.2 (68.5) 
Redundancy 2.5 (2.2) 
No. of 
Molecules/asymmetric unit 
4 
Refinement  
Resolution (Å) 30-1.9 
No. reflections 357,226 
Rcrystal / Rfree 0.212/0.243 
No. atoms  
Protein 13,272 
Water 424 
B-factors(Å2)  
Protein 41.1 
Water 39.3 
R.m.s. deviations  
Bond lengths (Å) 0.007 
Bond angles (°) 
Ramachandran plot 
Most favored (%) 
Additional allowed (%) 
Generously allowed (%) 
Disallowed (%) 
1.4 
 
86.7 
12.5 
0.8 
0.0 
*Values in parentheses are for highest-resolution shell. 
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Glutamax, B27 supplement, and Primocin 10-14 days prior to use. 
Cells were treated with 20 nM HCR overnight at 37°C, washed three 
times in cold Hank’s Balanced Salt Solution (HBSS) and fixed with 4% 
(w/v) paraformaldehyde solution/(w/o) sucrose in PBS for 30 min at 
4°C. Bound HCR was detected by immunofluorescence using mouse 
anti-FLAG (clone M2 1:1000) and goat anti-mouse IgG Alexa 488 or 
633 (1:500). Endogenous proteins were detected by rabbit anti-
synaptophysin (1:200) and anti-rabbit IgG Alexa 488 or 633. A 
recombinant cholera toxin B subunit conjugate (Alexa 555) was used 
to detect ganglioside GM1a in lipid raft fractions. Cells were processed 
using standard immunofluorescence procedures, mounted in ProLong 
Gold Antifade reagent, and acquired using a Leica SPE-2 in confocal 
scanning mode. 
 
2.4 Results 
 
2.4.1 Optimizing HCR/T to bind Sia5 dependent gangliosides 
TeNT is unique among the CNTs because it is sorted into the 
retrograde axonal pathway and because it binds with high affinity to 
GM1a - a ganglioside that does not contain the Sia5 sugar [33, 103, 
111, 118]. Our hypothesis was: binding to ganglioside GM1a is 
required to sort TeNT into the retrograde axonal pathway. In order to 
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test whether GM1a plays a role in TeNT retrograde axonal trafficking, a 
variant of HCR/T dependent on the Sia5 sugar for binding at the W site 
was designed. Our strategy was to modify the conserved binding 
pocket of TeNT and incorporate structural features that confer Sia5 
binding as occurs in the evolutionarily related BoNTs. 
 As described in the Introduction, HCR/T contains two physically 
separate binding sites: the sialic acid binding site, or R site, and the W 
or tryptophan site. Therefore, to investigate binding solely at the W 
site it is necessary to inactivate the R site. This was achieved through 
generation of a previously described mutated variant HCR/T-R1226L 
[102, 111] (Figure 6). Amino acids that contribute to Sia5 binding in 
the BoNTs were identified using the crystal structure of HCR/F in 
complex with the oligosaccharide moiety of GD1a (PDB: 3RSJ) in 
conjunction with a sequence alignment of HCRs A, E, F, and T [47]. 
F1240 (BoNT/F numbering) was selected due to: (i) conservation with 
other BoNT serotypes and (ii) the deleterious effect of F1240 mutation 
on ganglioside binding (Figure 4 and Figure 8, Baldwin lab, personal 
communication). R1111 was selected because it creates a bond to Sia5 
in HCR/F and L1110 was selected because it may support the 
positioning of R1111 [71].  
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HCR/B HCR/B_I1239F HCR/B_I1239A 
3217  ± 193.5 119.4  ± 7.6 940742  ± 1.7e+006 
   
HCR/F HCR/F_F1240I HCR/F_F1240A 
40.84 ± 2.9 357.5 ± 25.12 465731 ± 1.4e+006 
A.  
B. 
 
Figure 8. Binding of wild type and mutated HCRs to ganglioside GT1b. (A) 
HCR/F (●), HCR/FF1240I (■) (corresponding amino acid in HCR/B), and HCR/FF1240A (▲) 
were incubated with 5µg GT1b (B) HCR/B (●), HCR/BI1239F (■), (corresponding amino 
acid in HCR/F), and HCR/BI1239A (▲) were incubated with 5µg GT1b. Wild type HCRs 
and variants were incubated with indicated concentration of GT1b and assayed for 
binding as described in Chapter 2 Methods. All values represent the arithmetic mean± 
SD of 3 independent experiments performed in triplicate. Data were plotted using 
GraphPad Prism. 
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The reciprocal point mutations in HCR/T: T1270F, A1134L, and 
S1135R were generated on the HCR/TR1226L background using site 
directed mutagenesis, creating the variant HCR/T A1134L, R1226L, T1270F, 
S1135R (hereafter referred to as HCR/TARTS). After verifying the correct 
mutations were introduced as described in Methods, HCR/TARTS was 
expressed, purified, and screened using the solid phase binding assay 
to determine half maximal binding affinity (B50) on ganglioside 
containing Sia5 (GD1a) and ganglioside lacking Sia5 (GM1a). The 
binding affinities of HCR/TARTS for GD1a and GM1a were ~30 nM and 
~60 nM which are similar to the previously reported B50 values of ~75 
nM for HCR/TR1226L for both GD1a and GM1a. These data suggest (i) 
additional interactions with Sia5, if present, do not enhance HCR/TARTS 
binding to Sia5 containing gangliosides or (ii) existing GA1 core 
interactions have higher affinity compared to new interactions with 
Sia5. In order to determine if core GA1 affinity was masking 
interactions with Sia5, unique interactions between HCR/T and the 
GA1 core were identified. (Figure 5 and Figure 9). 
HCR/T contains a, N1219, unique amino acid that coordinates 
binding to GA1 through GalNAc3. When previously characterized, 
HCR/TR1226L/N1219A abrogated ganglioside binding [47].  
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 ARTS 
GD1a 16.51 ± 2.978 
GM1a 80.34 ± 14.63 
 
 
Figure 9. Binding of HCR/TARTS to gangliosides GD1a and GM1a. Immobilized 
gangliosides (5µg) GD1a (●) or GM1a (■) were incubated with indicated 
concentrations of HCR/TARTS and assayed for binding as described in Chapter 2 
Methods. All values represent the arithmetic mean ±	SD of 2 independent 
experiments performed in duplicate. Data were plotted using GraphPad Prism version 
5 (GraphPad Software Inc.) 
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Similarly, HCR/TARTS/N1219A inhibited all ganglioside binding. Additional 
point mutations were tested (N1219S, N1219V) and both point 
mutations were equally inhibitory to ganglioside binding, creating 
affinities below the limit of detection of our assay for both GD1a and 
GM1a. Further mutation of HCR/T-N1219 was not pursued  
 
2.4.2 HCR/T-BoNT loop chimeras display altered ganglioside 
binding properties 
 Based on the observation that HCR/TARTS was not significantly 
altered in ganglioside binding, additional mutations designed to 
increase binding to Sia5 were considered. BoNT/A (S1275) and BoNT/F 
(R1256) both contain additional amino acids that could provide 
potential interactions with the Sia5 sugar. However, direct substitution 
of these residues with the corresponding positions in HCR/T was not 
possible due to differences in the orientation of the main chain 
backbone in these regions. Therefore, it was decided to attempt to 
swap the entire loop region of HCR/T with the equivalent regions from 
BoNTs A, E, and F. The initial exchange was performed with BoNT/F to 
maintain consistency with the previously introduced substitutions.  
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Using SOE-PCR, the corresponding amino acids in HCR/T (1293 
through 1300) were replaced with the BoNT/F amino acids (1254-
1263) in the HCR/TARTS background, creating HCR/TARTS-FLoop HCR/T-
BoNT loop chimeras were purified as described in Methods and 
analyzed for relative binding affinity to GD1a and GM1a using the solid 
phase binding assay. Further testing suggested HCR/TARTS-FLoop and 
HCR/TR1226L do not have significantly different affinity for GD1a or 
GM1a (Figure 10). Based on these data, two additional loop chimeras 
were generated containing BoNT/A residues 1270-1279 and BoNT/E 
residues 1228-1237. In comparison, HCR/TARTS-ALoop was stably 
expressed and preliminary screening indicated HCR/TARTS-ALoop bound 
ganglioside GD1a with similar affinity to HCR/TR1226L, while binding to 
GM1a was not evident (Figure 11). Based on these observations the 
binding properties of HCR/TARTS-ALoop were characterized further. The 
HCR/TARTS-ELoop protein was successfully cloned but not pursued 
further. 
 
2.4.3 Crystal structure of the variant HCR/TA1134L, T1270F, S1135R-
ALoop (HCR/TMO) 
 While HCR/TARTS-ALoop appeared to bind ganglioside in a Sia5 
dependent manner,  
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R1226L/GD1a ARTS-FLoop/GD1a R1226L/GM1a ARTS-FLoop/GM1a 
49.0 ± 6.3 6.213  ±  0.8 11.53  ± 2.4 12.9  ± 3.5 
 
 
Figure 10. Binding of HCR/TARTS FLoop to gangliosides GD1a and GM1a. 
Gangliosides GD1a and GM1a were incubated with HCR/TR1226L (▼/▲) and HCR/TARTS 
FLoop (r/s). Gangliosides were incubated with indicated concentrations of HCR/T 
variants and assayed for binding as described in Chapter 2 Methods. All values 
represent the arithmetic mean ± SD of at least 3 independent experiments performed 
in triplicate. Data were plotted using GraphPad Prism version 5 (GraphPad Software 
Inc.) 
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Figure 11. Binding of HCR/TARTS ALoop to gangliosides GD1a and GM1a. 
Gangliosides GD1a and GM1a were incubated with HCR/T variants HCR/TR1226L (▼/▲) 
and HCR/TARTS ALoop (¯/u). Gangliosides GD1a or GM1a were incubated with 
indicated concentrations of HCR/T variants and assayed for binding as described in 
Chapter 2 Methods. All values represent the arithmetic mean ± SD of at least 3 
independent experiments performed in triplicate. Data were plotted using GraphPad 
Prism version 5 (GraphPad Software Inc). 
 
  
 50 
 
it is important to emphasize that restoration of the sialic acid, or “R”, 
binding site (R1226) is essential to determine the consequences of 
these alterations in the context of in vivo binding. Therefore, to further 
characterize the binding properties of HCR/TARTS-ALoop, (lacking the R 
site, R-) three further variants were created: HCR/TA1134L, T1270F, S1135R-
ALoop (HCR/TARTS-ALoop with restored R site, hereafter dubbed HCR/TMO); 
HCR/T-W1289A, A1134L, T1270F, S1135R-ALoop (R site only, no W site or W-); 
and HCR/T-W1289A, A1134L, R1226L, T1270F, S1135R-ALoop (R-/W-). The inclusion 
of the W1289A mutation acts to inhibit all binding at the GA1 core 
binding site, thereby allowing direct investigation of binding to the 
restored R site. Using the solid phase binding assay, the binding profile 
of the HCR/T variants at 1 µM was determined using a range of 
gangliosides capable of interacting with either the R or W sites or both. 
In Figure 12, the comparison of HCR/T and HCR/TMO indicates 
restoration of R1226 in the HCR/TARTS-ALoop background reconstituted 
binding to GM1a. Additionally, ganglioside GD3, a ganglioside 
previously shown to specifically bind to the R site of HCR/T [103] had 
higher affinity for HCR/TMO/W1298A as compared to HCR/T W1298A. These 
data suggest ganglioside affinity at the R site may be increased in 
HCR/TMO relative to HCR/T.  
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Figure 12. Binding of HCR/T and mutated HCRs to multiple gangliosides. 1 
µM: HCR/T, HCR/TTMO, HCR/TTMO(W-), HCR/TARTSALoop(R-), HCR/TARTSALoop(R-/W-), and 
HCR/T(W-) were incubated with gangliosides GT1b (dark gray), GD1b (white), GD1a 
(light gray), GM1a (white with dark gray squares) and GD3 (white with dark gray 
stripes). Gangliosides were incubated with HCR/T or indicated variants and assayed 
for binding as described in Chapter 2 Methods. All values represent the arithmetic 
mean ± SD of at least 2 independent experiments performed in duplicate. Data were 
plotted using GraphPad Prism version 5 (GraphPad Software Inc.) 
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In order to gain further insight into the role of the HCR/TARTS-ALoop 
mutations in ganglioside binding, HCR/TMO was crystallized by Zhuji Fu 
in the lab of Dr. Jung Ja Kim at the Medical College of Wisconsin. The 
structure of recombinant HCR/TMO was determined to a resolution of 
1.9 Å by the molecular replacement method using the monomer 
structure of HCR/T complexed with GT2 (PDB: 3HMY) as the search 
probe. The overall structure of HCR/TMO was highly similar to HCR/T, 
with an overall root mean square deviation of 0.3 Å (398 Cα atoms), 
with the notable exception of loop residues 1293-1300 which adopt an 
alternate conformation as compared to HCR/T (Figure 13). Using the 
structure provided by the Jung Ja Kim lab, a superposition of HCR/TMO 
and HCR/T in complex with GT1b oligosaccharide (PDB: 1FV2) was 
created. Molecular docking of the oligosaccharide moiety of GT1b into 
HCR/TMO suggests that the overall binding mode is similar to HCR/T 
with additional hydrogen bonds between HCR/TMO and Sia5 formed by 
R1135 and R1299 and one bridging water molecule. 
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Figure 13. Superposition of HCR/T and HCR/TMO binding pockets. 
A ribbon representation of HCR/TMO and the GT1b oligosaccharide from HCR/T (PDB 
1FV2) (stick representation) are shown. HCR/TMO residues able to bind the GT1b 
oligosaccharide are colored in atomic color. Potential interactions with Arg1135 and 
Arg1299 are indicated. Superposition created from HCR/TMO provided by Jung Ja Kim 
Lab, Medical College of Wisconsin. Superposition created by Joshua Burns. 
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2.5 Discussion 
TeNT is unique among the CNTs because it is sorted into the 
retrograde axonal pathway and because it binds with high affinity to 
GM1a - a ganglioside that does not contain the Sia5 sugar [33, 103, 
111, 118]. In order to test whether GM1a plays a role in TeNT 
retrograde axonal trafficking, a variant of HCR/T dependent on the 
Sia5 sugar for binding at the W site was designed. Our strategy was to 
modify the binding pocket to incorporate structural features that 
confer Sia5 binding to the evolutionarily related BoNTs. Amino acid 
substitutions were initially introduced into HCR/T based on residues 
previously demonstrated to be important for ganglioside binding in 
BoNT/F. HCR/TARTS contained three mutations (T1270F, A1134L, and 
S1135R) designed to promote interactions with Sia5; yet initial 
screening suggested the introduced changes did not significantly alter 
binding to gangliosides GD1a or GM1a (Figure 9). However, mutation 
of HCR/T T1270F alone resulted in a dramatic decrease in binding to 
GD1a (Figure 14), suggesting that mutations A1134L and/or S1135R 
may interact with T1270F to restore binding. Although the exact role 
of the phenylalanine is unclear, previous studies in  
 
.  
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Figure 14. Binding of HCR/T variants to GD1a ganglioside. GD1a ganglioside 
was incubated with HCR/T variants HCR/TR1226L (▲), HCR/TR1226L/T1270F (É) and 
HCR/TR1226LALoop (). Ganglioside was incubated with indicated concentrations of 
HCR/T variants and assayed for binding as described in Chapter 2, Methods. All 
values represent the arithmetic mean ± SD of 2 independent experiments performed 
in duplicate. Data were plotted using GraphPad Prism version 5 (GraphPad Software 
Inc.) 
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BoNTs A, B, and F demonstrate this residue plays an important role in 
recognition of Sia5 (Figure 8), possibly by forming a stacking 
interaction with the hydrophobic face of the sugar ring. It was  
therefore hypothesized that more global changes in the Sia5 binding 
pocket between BoNTs and TeNT may also indirectly regulate 
ganglioside binding. In support of this model, replacement of 
a structurally divergent loop region within HCR/T (residues 1293-
1300) with the corresponding sequences of BoNT/F and BoNT/A 
caused significant reductions in GM1a binding (Figures 10 and 11). 
Indeed, insertion of the A loop sequence alone was sufficient to abolish 
binding to both GD1a and GM1a (Figure 11). These data argue that 
recognition of Sia5 is a multifaceted process that regulates binding of 
the GA1 core sequence to the GBM. Previous structural and 
biochemical data suggest GM1a does not bind the R site of TeNT, 
presumably because the affinity for the Gal2-linked sialic acid is not 
sufficient [102, 103, 111]. Unexpectedly, restoration of the R site in 
HCR/TARTS-ALoop background, generating HCR/TMO, restored GM1a 
binding to near wild-type levels (Figures 12 and 15). Binding of 
HCR/TMO to ganglioside was further probed using GD3 which was 
previously shown to bind exclusively to the R site [103, 111, 129] 
(Figure 16).  
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Figure 15. Binding of HCR/T variants to GM1a ganglioside. GM1a ganglioside 
was incubated with HCR/T (●), HCR/T(W-) (-), HCR/TTMO (o), HCR/TTMO(W-) (¬), 
HCR/TARTSALoop(R-) (¯) and HCR/TARTSALoop(R-/W-)(x). Ganglioside was incubated with 
indicated concentrations of HCR/T or variant and assayed for binding as described in 
Chapter 2, Methods. All values represent the arithmetic mean ± SD of at least 3 
independent experiments performed in triplicate. Data were plotted using GraphPad 
Prism version 5 (GraphPad Software Inc.) 
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Figure 16. Binding of HCR/T variants to GD3 ganglioside. GD3 ganglioside was 
incubated with HCR/T (●), HCR/T(W-) (-), HCR/TTMO (o), HCR/TTMO(W-) (¬), 
HCR/TARTSALoop(R-) (¯) and HCR/TARTSALoop(R-/W-)(x). Ganglioside was incubated with 
indicated concentrations of HCR/T or variant and assayed for binding as described in 
Chapter 2, Methods. All values represent the arithmetic mean ± SD of at least 4 
independent experiments performed in triplicate. Data were plotted using GraphPad 
Prism version 5 (GraphPad Software Inc.) 
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Contrary to expectations, HCR/TMO has an elevated affinity for GD3 as 
compared with wild type HCR/T. In addition, mutation of the 
conserved GBM Trp residue confirmed GD3 binding was to the R site 
alone. These data imply that mutations at the W pocket have altered 
the affinity of the R site for ganglioside. However, the mechanistic 
basis for this claim is unclear given that the HCR/TMO crystal structure 
does not reveal any significant changes in the R site. Although binding 
of HCR/TMO was clearly observed in the solid phase binding assay, 
previous studies suggest ganglioside interactions occurring on cellular 
membranes are less promiscuous. To determine if the observed affinity 
for GM1a was an artifact of the plate assay, binding and entry into 
Neuro2a cells exogenously loaded with GM1a was determined under 
the conditions described by Chen et al. [103]. In agreement with 
previous observations, loading cells with GM1a alone was not sufficient 
to induce binding and entry of HCR/TMO, suggesting the R site was not 
able to bind GM1a [102, 103]. When Neuro2a cells were similarly 
loaded with GT1b or an equimolar mixture of GD3/GM1a (gangliosides 
binding to the R and W sites of TeNT respectively) HCR/TMO was able 
to bind and internalize efficiently (Figure 17A). Moreover, when 
HCR/TARTS-ALoop was added to Neuro2a  
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A. 
B. 
NT GM1a GT1b GD3/GM1a 
HCR/T 
HCR/T
MO 
HCR/T
ARTS
ALoop 
NT Any ganglioside 
Figure 17(A-B). HCR/TMO enters cells similar to HCR/T. (A) Exogenous 
gangliosides GM1a, GT1b, or combination of GD3 and GM1a were added to 
Neuro2A cells prior to exposure to, HCR/T or HCR/TMO. HCRs were detected by 
FLAG epitope sequence and processed for immunofluorescence. (B) HCR/TARTS 
ALoop was similarly added to Neuro2A cells previously treated with GM1a, GT1b, 
or GD3 and GM1a, detected by FLAG epitope sequence and processed for 
immunofluorescence. No binding was detected under any conditions. 
Representative of images from 5 images. 
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cells similarly loaded with gangliosides no binding above untreated 
control cells was observed (17B). These data suggest that recognition 
of GM1a by HCR/TMO in the solid phase binding assay does not extend 
to GM1a in the context of a biological membrane. Rather, the data 
argue that similar to wild type HCR/T, the R site of HCR/TMO 
preferentially recognizes disialic acid moieties on the cell surface. 
 
2.6 Future Directions 
 At present the precise mechanism(s) by which HCR/TMO 
recognizes gangliosides remains unresolved. Future studies designed 
to shed more light on the binding mechanism include using mass 
spectroscopy to determine the molar ratios of ganglioside to protein in 
the bound complexes (similar to the procedure of Rummel et al.) 
[102]. If successful, the approach could independently confirm the 
ability of HCR/TMO to bind GM1a in solution and verify if binding was to 
the R site specifically. Similarly, a co-crystal of HCR/TMO bound to 
either GD1a or GT1b would provide direct evidence for interactions 
between the Sia5 sugar and HCR/TMO. In order to determine if the R 
site has higher binding affinity as compared to HCR/T, we could use a 
more sensitive technique to measure binding, such as surface plasmon 
resonance, to determine if there is difference in R site affinity.  
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The major unanswered question however, is if there is a difference in 
retrograde trafficking as compared to HCR/T. Preliminary experiments 
using ex vivo cultures of rat cortical neurons suggest that HCR/TMO 
binds differently to cells than HCR/T. Colocalization experiments 
demonstrate that HCR/TMO segregates more efficiently with the cholera 
toxin B subunit (a marker of lipid rafts) than does HCR/T (Figure 17 
C-E). However, this still does not directly address the issue of 
retrograde axonal trafficking. An attempt to look at retrograde axonal 
trafficking directly in cultured motor neurons in collaboration with Dr. 
Gipi Schiavo’s laboratory was initiated [33, 130]. However, the only 
response received thus far was that overall binding of HCR/TMO to 
motor neurons was reduced by ~20% as compared to wild type. We 
could evaluate the ability of HCR/TMO to undergo retrograde axonal 
trafficking using a live rat model by looking for a difference in hind 
limb pathology [131]. Based on the summation of our data, it is not 
clear that investing in animals and a pathologist is best at this time 
because we are not able to describe a definite binding mechanism to 
HCR/TMO, or define how the binding mechanism is different from 
HCR/T.  
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Figure 17 (C-E). Colocalization of tetanus toxin HCR domains with cholera 
toxin b subunit at 37°C and 4°C. (A) Rat primary cortical neurons were exposed 
to either 10 nM HCR/T (upper panels) or 10 nM HCR/T-MO (lower panels) in the 
presence of 10 nM cholera toxin b subunit (CTxB) for 15 minutes at 37°C. Cells were 
subsequently fixed and HCR detected by indirect immunofluorescence as described in 
the Methods section. (B) Neurons were treated exactly as described in (A), except 
that the temperature was shifted to 4°C. (C) Colocalization of TeNT HCRs with 
cholera toxin b subunit (CTxB) was determined by the method of Manders et 
al.[132]. Data was analyzed by two-way ANOVA and Holm-Sidak's multiple 
comparisons test with an alpha value of 0.01. Colocalization indexes M1 and M2 are 
defined by: ∑S1i,coloc / ∑S1i and ∑S2i,coloc / ∑S2i respectively. ∑S1i and ∑S2i 
represent signal intensities in the green (S1) and red (S2) channels. ∑S1i, coloc and 
∑S2i,coloc represent those pixels that display non-random fluorescence in the 
opposite channel, n=15 random fields. Data are an average of 2 biological repeats. 
  
E. 
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Additionally, recent data suggest TeNT holotoxin may undergo 
retrograde axonal trafficking more efficiently than HCR/T alone, 
suggesting regions of the molecule outside the HCR contribute to 
cellular sorting [133]., If appropriate technologies become available 
studies designed to test the role of GM1a in retrograde axonal 
trafficking may be undertaken with HCR/TMO holotoxin or HCR/TMO.  
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CHAPTER 3: UNIQUE GANGLIOSIDE RECOGNITION 
STRATEGIES FOR BOTULINUM A1 and A2 
 
3.1 Abstract 
Botulinum neurotoxins (BoNTs) have been identified as Tier 1 category 
“A” Select Agents by the Centers for Disease Control and Prevention. 
Currently, seven BoNT serotypes (A-G) and ~40 subtypes have been 
identified. Sequencing of BoNT/A genes from multiple isolates of 
Clostridium botulinum have revealed a high degree of sequence 
variability, and so far, eight BoNT/A subtypes (BoNT/A1-8) have been 
identified. Two subtypes, BoNT/A1 and BoNT/A2, share a high degree 
of amino acid sequence identity (~89%), yet BoNT/A2 has significantly 
enhanced toxicity compared to BoNT/A1. While available data suggests 
the enhanced toxicity of BoNT/A2 may result from increased efficiency 
of binding and entry, the mechanistic basis for this remains unclear. 
Paradoxically, structural predications suggest ganglioside interactions, 
and specific interactions with the Sia5 sugar, may be present in 
BoNT/A1 that may not exist in BoNT/A2. This implied that BoNT/A2 
would bind ganglioside with lower affinity than BoNT/A1. However, a 
solid-phase binding assay demonstrated that the affinity of A1 and A2 
for gangliosides was similar. Further biochemical characterization 
revealed that two previously proposed protein-carbohydrate 
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interactions [Tyr1117 (OH): Sia5 and Ser1264 (OG): Sia5] do not 
significantly contribute to ganglioside binding. Indeed, it appears that 
the presence of the tyrosyl side chain in A1 or the phenyl side chain in 
A2 (Phe1117) reduce binding to Sia5 containing gangliosides. Cellular 
binding assays demonstrate that HCR/A1Y1117A and HCR/A2F1117A enter 
cells faster than parental domains and suggest a strategy for 
improving the toxicity and hence therapeutic benefits of botulinum 
neurotoxins.  
 
3.2 Introduction 
 Recognition of botulism in the 1820s lead to the discovery and 
early characterization of botulinum neurotoxin (BoNT) in the 1890s. 
Increasing outbreaks established that unique, antigen specific BoNT 
toxins were capable of causing disease [134]. Modern sequencing 
technology and access to bacterial strains has provided a platform to 
begin comprehensive study of BoNT diversity. Currently, seven 
serotypes and over 40 BoNT subtypes have been identified. Overall 
amino acid composition of a subtype must differ by at least 2.5% to be 
unique, but can be up to 30% different in some cases [135, 136]. 
Botulinum neurotoxin type A1 (BoNT/A) is produced by C. botulinum 
group I isolates and is considered the parental toxin for all clostridial 
neurotoxins including tetanus toxin. There are currently 8 described 
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subtypes for BoNT/A (A1-A8). BoNT/A1 (parental), BoNT/A2 originally 
isolated from a patient in Kyoto, Japan [137, 138], BoNT/A3 was 
responsible for a famous outbreak at a hotel in Loch Maree, Scotland 
in 1926 [139, 140], BoNT/A4 was isolated from a strain of C. 
botulinum that produces both A and B toxins [141], BoNT/A5 was 
recently isolated in 2010 from a patient in Wisconsin [142], BoNTs A6 
and A7 were recently described from patients in France [143, 144], 
and BoNT/A8 has also been recently described [145]. Vaccine studies 
confirm CNT subtypes are neutralized by vaccination with 
corresponding subtypes but levels of cross-protection and neutralizing 
epitopes are different [97, 140, 146]. 
 Functional characterization of BoNT/A subtypes has been 
undertaken. The gold standard for determining BoNT toxicity has been 
the mouse bioassay (MBA) [147, 148]. Using mouse LD50s, specific 
activities of individual BoNTs can be compared. MBA results indicated 
the specific activity (U/mg) for BoNT A1(1.25 x 108) = A2(1.24 x 108) 
~ A5(1.4 x 108) > A3(5.8 x 107) >A4(1.25 x 105) [148].  Analysis 
using cultured primary neurons, rodent twitch tension, and grip 
strength assays suggested BoNT/A2 was more potent than BoNT/A1 
[149, 150]. In accord, data collected using rodent primary neurons 
and neurons derived from human induced pluripotent stem cells, 
suggested the effective concentration of BoNT/A2 resulting in 50% 
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cleavage of SNAP-25 (EC50) was tenfold lower than the EC50 for 
BoNT/A1 [148]. Moreover, BoNT/A2 intoxicated mice were noted to 
have experienced a more rapid onset of death than BoNT/A1 
intoxicated mice with paralysis similar to BoNT/A3 intoxicated mice. 
[148]. These data suggest BoNTs A2 and A1 may target unique 
subsets of neurons after neuronal entry. 
The molecular basis for the apparent increased potency of 
BoNT/A2 as compared with the remaining A subtypes is not currently 
understood. Analysis of catalytic efficiency determined BoNTs A1 and 
A2 cleaved SNAP-25 in vitro with similar kinetic efficiency, BoNT/A3 
had half the activity of BoNT/A1, and BoNT/A4 was tenfold less active 
than BoNT/A1 [151, 152]. Thus the activity of the LC does not appear 
to be responsible for the increased toxicity of A2. Interestingly, when 
recombinant HCR derivatives (HCR/A1 and HCR/A2) were applied to 
rat primary spinal cord neurons and mouse Neuro2A cells, HCR/A2 
entered cells more rapidly than HCR/A1 [149]. Moreover, studies with 
an inhibitor of BoNT LC translocation (toosendanin), suggested that 
the enhanced neurotoxicity of BoNT/A2 compared to A1 is due to more 
rapid translocation of LC/A2 or to a step in the intoxication process 
preceding translocation [149]. Thus it appears that differences in 
cellular binding and entry may account for the increased toxicity of A2 
in vivo. 
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A global alignment of BoNT/A1 with BoNT/A2 shows a high 
degree of amino acid sequence conservation (89%), with greater 
variability observed when comparing the four major structural domains 
of the toxins to each other (LC, 95%; HCT, 87%; HCRN, 83%; and 
HCRC, 90%) [151]. The structural elements involved in ganglioside 
recognition in BoNT/A1 have been well-characterized. BoNT/A1 
contains a conserved ganglioside binding motif (GBM; E…H…SXWY…G) 
which coordinates the GA1 carbohydrate core of gangliosides 
containing Sia5. Mutation of the central tryptophan residue (W1266L) 
increased paralytic halftime and reduced binding to rat brain 
synaptosomes and immobilized ganglioside similar to TeNTW1289A [102, 
153]. Predictably, mutation of the remaining GBM residues also 
increased paralytic halftimes and decreased overall toxicity. More 
recently, a co-crystal of HCR/A with the oligosaccharide moiety of 
GT1b suggested that ganglioside binding was further stabilized by 
hydrogen bonds formed between Y1117, S1275, R1276, and Sia5 
[112]. However, biochemical confirmation of these interactions was 
not reported. Similar interactions were reported in a co-crystal of 
HCR/F with the oligosaccharide moiety of GD1a [47, 112], suggesting 
interactions with Sia5 may be essential for BoNT ganglioside 
recognition. Our hypothesis is that interactions between BoNT/A2 and 
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the Sia5 sugar are required for efficient binding and entry and 
contribute to increased toxicity. 
Development of BoNT/A2 will expand current BoNT utility in 
pharmaceutical applications, broaden our insight into inhibitor design, 
and expand our knowledge of BoNT entry mechanisms. However, the 
current lack of understanding of BoNT/A2 entry and toxicity 
mechanisms is preventing full development of the BoNT/A2 platform. 
This research in conjunction with other ongoing programs will shed 
light on the entry and toxicity mechanisms of the BoNT/A serotype 
specifically and more generally the clostridial neurotoxins. 
 
3.3 Experimental procedures 
 
3.3.1 Cloning and mutagenesis of HCR and TEM-Bla_BoNT/A 
fusion proteins 
 A previously described, modified, pET28a expression vector 
(Novagen) – hereafter referred to as pET28-3×FLAG – containing a 
3×FLAG epitope immediately downstream of the hexahistidine epitope 
tag was used as the expression vector for all HCR constructs [125]. 
Briefly, E. coli optimized HCR DNA (aa 873-1295) was chemically 
synthesized (Genscript, Inc) and subcloned into pET28-3×FLAG via 
unique 5’ KpnI and 3’ XhoI restriction sites. Point mutations were 
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introduced into the HCR/A1 and A2 genes by site directed mutagenesis 
using Quikchange® II Site-Directed Mutagenesis Kits (Agilent) and 
confirmed by DNA sequencing. 
 TEM-Bla reporter proteins: the TEM-Bla gene from pUC57 was 
amplified by PCR, ligated into the NcoI and NdeI sites of pET28a, and 
confirmed by DNA sequencing. Subsequently, synthetic DNA fragments 
encoding BoNT/A1 residues 1-846 and 845-1295 were sequentially 
cloned into pET28a harboring the TEM-Bla gene using NdeI, ScaI, and 
XhoI restriction sites. The BoNT/A2 construct was generated in a 
similar manner. In both cases, the toxin gene contained three point 
mutations (E224A, R363A, and Y366F) which inactivate the enzymatic 
activity of LC resulting in non-toxic proteins.   
 
3.3.2 Expression and purification of HCR and TEM-Bla_BoNT/A 
fusion proteins 
 WT and mutated HCRs were expressed and purified as previously 
described in Chapter 2 methods, section 2.2.3. In addition to an N-
terminal hexahistadine tag, TEM-Bla_BoNT/A1 and A2 contain C-
terminal Strep-Tag II® epitopes. pET28a-TEM-Bla_BoNT/A1 or A2 
DNA was transformed into BL-21 (DE3) Ai cells and cultured on LB-Kan 
plates overnight. Expression and purification of pET28a-TEM-
Bla_BoNT/A1 was performed under similar conditions to those 
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described in Chapter 2 methods, section 2.2.3. After 3 hours at 37ºC 
at 250 r.p.m bacteria were induced with a final concentration of 1 mM 
IPTG and 5% L-Arabinose. Incubation continued overnight following 
temperature reduction to 16ºC.  Following overnight culture, TEM-
Bla_BoNT/A1 was isolated by sequential chromatography using 
Streptactin-sepharose and Ni-NTA-agarose and subsequently dialyzed 
into PBS. 
 
3.3.3 Solid phase ganglioside binding assay 
 The solid phase binding assay was carried out as described in 
Chapter 2 Methods, section 2.2.4. WT and mutated HCRs were added 
to 96 well plates containing previously immobilized ganglioside GT1b. 
Post incubation, an antibody solution containing anti-FLAG M2 
monoclonal antibody (1:8,000) and goat anti-mouse poly HRP 
(1:10,000; Pierce) was prepared to detect bound HCR complexes. 
Bound HCR complexes were detected using Ultra TMB (Pierce) as the 
HRP substrate. The reaction was terminated by addition of an equal 
volume of 0.1 M H2S04. The absorbance at 450 nm was determined 
using a plate reader (BioTek). The concentration of HCR required to 
give 50% of maximum binding (B50) was estimated. 
 
3.3.4 HCR binding to rat cortical neurons 
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 As described in Chapter 2 Methods, section 2.2.6, rat embryonic 
day 18 (E18) cortical neurons (Brainbits) were mechanically 
dissociated per the Brainbits, llc protocol and cultured in supplemented 
Neurobasal medium on poly-D-lysine coated cover slips 10-14 days 
prior to use. Cells were treated with 10, 50, and 250 nM HCRs for 5 
min. in neuron stimulation buffer (15 mM HEPES, 95 mM NaCl, 56 mM 
KCl, 2.2 mM CaCl2, 0.5 mM MgCl2, pH 7.4), washed three times in 
cold Hank’s Balanced Salt Solution (HBSS), and fixed in 4% (w/v) 
paraformaldehyde/4% (w/v) sucrose solution in PBS for 30 min at 
room temperature. Cells were subsequently quenched with 0.1M 
glycine, permeabilized with 0.25% (v/v) Triton X-100, and blocked 
using Image-IT reagent. Bound HCR was detected by 
immunofluorescence using mouse anti-FLAG (clone M2 1:1000) and 
goat anti-mouse IgG Alexa 488 (1:200). Endogenous synaptophysin 
was detected using rabbit anti-synaptophysin (1:100) and anti-rabbit 
IgG Alexa 568 (1:200). Cells were processed using standard 
immunofluorescence procedures, mounted in ProLong Gold Antifade 
reagent, and acquired using a Leica SPE-2 in confocal scanning mode. 
Colocalization was analyzed using Li’s Intensity Correlation Quotient 
(ICQ) equation within the JaCoP plugin module for ImageJ [154]. An 
average of 15 random fields and at least biological repeats were 
performed. Data were analyzed using unpaired student t-test. 
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3.3.5 LC translocation assay 
 TEM-Bla_BoNT/A1 was incubated with rat primary cortical 
neurons for a minimum of three hours at 37ºC. Cells were washed 
twice with HBSS and then loaded with the fluorescent TEM-Bla 
substrate CCF4-AM (ThermoFisher Scientific) for 90 min at room 
temperature. Cells were washed with HBSS, trypsinized, filtered to 
remove large cell aggregates, and analyzed by flow cytometry. Cells 
were excited at 405 nm, side scatter emission was set at 450/50 and 
forward scatter emission was set at 515/20 using a BD LSR Fortessa 
X-20 instrument. 
 
3.4 Results 
 
3.4.1 HCR/A2 enters neurons by way of recycling secretory 
vesicles 
Previous studies have demonstrated that the uptake of BoNT/A2 
into neurons is stimulated by conditions which promote synaptic 
vesicle exocytosis. Therefore, to further characterize the entry of 
BoNT/A2, a recombinant HCR domain containing the FLAG epitope was 
generated. In agreement with previous observations, little or no 
binding of HCR/A2 to rat primary cortical neurons was observed either 
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at 4°C or when cells were exposed to protein under non-depolarizing 
conditions (low K+ buffer) (data not shown). However, when cells 
were exposed to HCR/A2 under depolarizing conditions (high K+ 
buffer) a significant increase in binding and uptake was observed 
(Figure 18, panel A, green channel). Co-staining for the synaptic 
vesicle protein synaptophysin (Figure 18, panel B, red channel) 
suggested a qualitative relationship between the two proteins 
visualized in the merged image (Figure 18, panel C) as yellow pixels. 
The degree of colocalization was evaluated more quantitatively 
by performing Intensity Correlation Analysis. This is a method in which 
the intensities of the pixels in the green and red channels are 
compared statistically by calculating the PDM (Produce of the 
Differences of the Means) value for each pixel. When pixel intensities 
for either green or red channels are plotted as a function of the PDM 
values (Figure 18, panel D), it is clear that they are skewed towards 
positive values, consistent with a dependent staining pattern. 
Averaging of the calculated Intensity Correlation Quotient (ICQ) values 
for multiple fields gave a value of 0.263±0.04 which strongly supports 
this idea. By comparison, HCR/A2 was strongly segregated from the 
dendritic marker MAP2 (Figure 18, panel E) supporting the specificity 
of the HCR/A2–Synaptophysin colocalization.  
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Figure 18. HCR/A2 enters neurons by way of recycling secretory vesicles. 
(A) Rat cortical neurons were incubated for 5 min at 37°C in high K+ buffer to 
stimulate vesicle recycling. Cells were then washed, fixed, and permeabilized as 
described in the Methods section. Internalized HCR/A2 was stained using a mouse 
anti-FLAG antibody and an Alexa Fluor 488-conjugated goat anti-mouse secondary 
antibody. (B) The integral synaptic vesicle membrane protein Synaptophysin (SYP) 
was stained using a rabbit anti-SYP antibody and an Alexa Fluor 568-conjugated goat 
anti-rabbit secondary antibody. (C) An enlarged optical section of the region 
highlighted by the white box in panels A and B showing a high degree of co-
localization between the two proteins. (D) An intensity correlation plot for panels A 
and B showing dependent staining among the two variables in the study: HCR/A2 
and SYP [155]. (E) Quantification of Intensity correlation quotient (ICQ) values for 
HCR/A2 and SYP and HCR/A2 and Microtubule-associated protein 2 (MAP2), n=15 
random fields and ≥ 2 biological repeats. Data analyzed using unpaired t-test. 
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These data argue that similar to BoNT/A1, entry of BoNT/A2 is through 
recycling synaptic vesicles likely mediated by interactions with 
ganglioside and SV2 co-receptors.  
 
3.4.2 Sequence diversity in residues forming the ganglioside 
binding pocket of BoNT/A1 and BoNT/A2 
As outlined in the introduction, accumulating evidence suggests 
that differences in cellular binding and/or entry may account for the 
increased toxicity of BoNT/A2 relative to BoNT/A1 in vivo  One possible 
mechanism by which the entry of BoNT/A2 could differ is through 
unique interactions with ganglioside co-receptors. To begin to address 
this possibility, a homology model of HCR/A2 was generated using 
SWISS-Model (http://swissmodel.expasy.org/interactive) [156]. The 
co-crystal of HCR/A1 with GT1b oligosaccharide (PDB: 2VU9) was used 
as the template to generate the HCR/A2 model. Next, the HCR/A2 
model was overlaid with the co-crystal structure of HCR/A1 bound to 
GT1b (Figure 19). As expected, residues forming the GBM were 
conserved between A1 and A2, while residues predicted to make 
hydrogen bonds (S1275 and R1276) with Sia5 were similarly 
conserved  
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E1203 
H1253 
F1252 
S1264 
W1266 
R1276 
Q1270 
R1269 
S1275 
Y1117 
G1279 
Sia5 
Gal4 
Sia6 GalNAc3 
L1254 
Q1254 
D1256 
N1256 
Y1255 
F1255 
F1274 
L1274 
Figure 19. Superposition of HCR/A1 in complex with GT1b and a 3D 
homology model of HCR/A2. Overall structure of HCR/A1 is displayed as ribbon 
diagram with grey Cα. GT1b represented as sticks with yellow carbons. The GT1b 
coordinating residues are shown as sticks with grey carbons. The HCR/A2 residues 
which vary with HCR/A1 are shown as sticks with cyan carbons.  
F1117 
Adapted from PDB: 2VU9. PLoS Pathog. 2008 Aug 15;4(8):e1000129. PMID: 18704164 
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However, HCR/A1 Y1117 – which is predicted to form two hydrogen 
bonds to Sia5 – was replaced by phenylalanine in HCR/A2. In addition, 
several other residues which contribute to the overall structure of the 
ganglioside binding pocket were also not conserved between the A 
subtypes. 
 
3.4.3 HCR/A1 and HCR/A2 bind ganglioside GT1b with similar 
affinity 
 To determine what effect amino acid differences in the 
ganglioside binding pocket may have on ganglioside binding, 
wild-type and variant proteins were compared directly using a solid-
phase binding assay (Solid phase binding assays were carried out with 
assistance from Greg Lambert). HCR/A1 and HCR/A2 bound GT1b with 
similar affinity (~150 nM for A2 and ~250 nM A1) (Figure 20A and 
Table 6). HCR/A1S1275 and HCR/A2S1275 variants were created and 
were similarly unaffected in the ability to bind ganglioside (Table 6). 
The co-crystal structure of HCR/A1 bound to GT1b suggested that 
Y1117 forms two hydrogen bonds to Sia5. Consequently, the 
equivalent position in HCR/A2 with phenylalanine (F1117) was 
expected to have reduced ganglioside binding. However, both 
increased affinity to GT1b when mutated to alanine (Figure 20B).  
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Figure 20. Binding of HCR/A variants to ganglioside. (A) GT1b ganglioside was 
incubated with HCR/A1 (●), HCR/A2. (■) or (B) HCR/A1Y1117A or HCRA2F1117A. 
Ganglioside was incubated with indicated HCRs and assayed for binding as described 
in Chapter 2, Methods. All values represent the arithmetic mean ± SD of ≥4 
independent experiments performed in duplicate. Data were plotted using GraphPad 
Prism version 5 (GraphPad Software Inc.) 
  
  
A. 
B. 
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Table 6. Binding affinities of BoNT/A HCRs 
 
Only values with a difference greater than 5 fold are considered significant.  
Significant values are marked with an asterisk (*). 
 
  
HCR B50
HCR/A1 263.5
HCR/A2 150.3
HCR/A1S1275A 193.6
HCR/A1Y1117F 243.7
HCR/A1Y1117A 11.04*
HCR/A2S1275A 243.4
HCR/A2F1117Y 103.6
HCR/A2F1117A 10.51*
 83 
 
It was decided to more fully address the role of Y1117 in binding to 
ganglioside. Mutational analysis revealed that ganglioside binding of 
HCR/A1Y1117F and HCR/A2F1117Y were largely unchanged, arguing 
against a major role for the tyrosine hydroxyl group in binding to Sia5 
(Table 6). Indeed, replacement of tyrosine or phenylalanine with 
alanine resulted in a significant increase in affinity of HCR/A1 and 
HCR/A2 respectively for GT1b (Figure 20B and Table 6.).Similarly, 
replacement of S1275 – another residue predicted to form a hydrogen 
bond to GT1b – with alanine did not cause a significant change in 
affinity (Table 6).  
 
3.4.4 HCR/A1Y1117A and HCR/A2F1117A increase efficiency of 
entry into cortical neurons 
 In order to determine if increased ganglioside binding efficiency 
in vitro resulted in more efficient cellular uptake, cortical neurons were 
treated with HCR/A1, HCR/A2, HCR/A1Y1117A, and HCR/A2F1117A under 
depolarizing conditions. Cells were subsequently fixed and internalized 
HCR was visualized by immunofluorescence microscopy. In agreement 
with previously published observations, uptake of HCR/A2 was more 
efficient than HCR/A1 at equivalent concentrations (Figure 21B).  
  
 84 
 
 
  
Figure 21. HCR/A1Y1117A and HCR/A2F1117A bind and enter neurons with 
higher efficiency. (A) Rat cortical neurons were incubated for 5 min at 37°C in high 
K+ buffer to stimulate vesicle recycling. Cells were then washed, fixed, and 
permeabilized as described in the Methods section. Internalized HCRs were stained 
using a mouse anti-FLAG antibody and an Alexa Fluor 488-conjugated goat anti-
mouse secondary antibody and the integral synaptic vesicle membrane protein 
Synaptophysin (SYP) was stained using a rabbit anti-SYP antibody and an Alexa 
Fluor 568-conjugated goat anti-rabbit secondary antibody for determination of ICQ 
values (B) n=15 random fields, 2 biological repeats. Statistical analysis using one 
way ANOVA. P ≤0.001. See analysis (see Table 7). 
  
anti-
FLAG 
(HCR) 
anti-SYP 
HCR/A1 HCR/A1
Y1117A HCR/A2 HCR/A2F1117A No toxin 
A 
B 
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Table 7. ANOVA Analysis and multiple comparisons for Figure 
21B. 
Number of families 1      
Number of comparisons 
per family 
66      
Alpha 0.05      
       
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant? Summary Adjusted P 
Value 
 
       
HCRA1_250 vs. 
HCRA1_50 
59.4 41.43 to 77.37 Yes **** < 0.0001 A-B 
HCRA1_250 vs. 
HCRA1_10 
73.74 55.78 to 91.71 Yes **** < 0.0001 A-C 
HCRA1_250 vs. 
HCRA1Y1117A_250 
-26.66 -44.63 to -8.695 Yes *** 0.0001 A-D 
HCRA1_250 vs. 
HCRA1Y1117A_50 
36.04 18.07 to 54.01 Yes **** < 0.0001 A-E 
HCRA1_250 vs. 
HCRA1Y1117A_10 
64.37 46.41 to 82.34 Yes **** < 0.0001 A-F 
HCRA1_250 vs. 
HCRA2_250 
-36.6 -54.57 to -18.64 Yes **** < 0.0001 A-G 
HCRA1_250 vs. 
HCRA2_50 
34.36 16.40 to 52.33 Yes **** < 0.0001 A-H 
HCRA1_250 vs. 
HCRA2_10 
64.95 46.98 to 82.92 Yes **** < 0.0001 A-I 
HCRA1_250 vs. 
HCRA2F1117A_250 
-35.14 -53.10 to -17.17 Yes **** < 0.0001 A-J 
HCRA1_250 vs. 
HCRA2F1117A_50 
-18.37 -36.33 to -0.4000 Yes * 0.0402 A-K 
HCRA1_250 vs. 
HCRA2F1117A_10 
18.91 0.9440 to 36.88 Yes * 0.0295 A-L 
HCRA1_50 vs. 
HCRA1_10 
14.34 -3.625 to 32.31 No ns 0.2633 B-C 
HCRA1_50 vs. 
HCRA1Y1117A_250 
-86.06 -104.0 to -68.10 Yes **** < 0.0001 B-D 
HCRA1_50 vs. 
HCRA1Y1117A_50 
-23.36 -41.33 to -5.395 Yes ** 0.0016 B-E 
HCRA1_50 vs. 
HCRA1Y1117A_10 
4.973 -12.99 to 22.94 No ns 0.9989 B-F 
HCRA1_50 vs. 
HCRA2_250 
-96 -114.0 to -78.04 Yes **** < 0.0001 B-G 
HCRA1_50 vs. 
HCRA2_50 
-25.04 -43.00 to -7.071 Yes *** 0.0005 B-H 
HCRA1_50 vs. 
HCRA2_10 
5.55 -12.42 to 23.52 No ns 0.997 B-I 
HCRA1_50 vs. 
HCRA2F1117A_250 
-94.54 -112.5 to -76.57 Yes **** < 0.0001 B-J 
HCRA1_50 vs. 
HCRA2F1117A_50 
-77.77 -95.73 to -59.80 Yes **** < 0.0001 B-K 
HCRA1_50 vs. 
HCRA2F1117A_10 
-40.49 -58.46 to -22.52 Yes **** < 0.0001 B-L 
HCRA1_10 vs. 
HCRA1Y1117A_250 
-100.4 -118.4 to -82.44 Yes **** < 0.0001 C-D 
HCRA1_10 vs. 
HCRA1Y1117A_50 
-37.7 -55.67 to -19.74 Yes **** < 0.0001 C-E 
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HCRA1_10 vs. 
HCRA1Y1117A_10 
-9.368 -27.33 to 8.599 No ns 0.8526 C-F 
HCRA1_10 vs. 
HCRA2_250 
-110.3 -128.3 to -92.38 Yes **** < 0.0001 C-G 
HCRA1_10 vs. 
HCRA2_50 
-39.38 -57.35 to -21.41 Yes **** < 0.0001 C-H 
HCRA1_10 vs. 
HCRA2_10 
-8.791 -26.76 to 9.175 No ns 0.8987 C-I 
HCRA1_10 vs. 
HCRA2F1117A_250 
-108.9 -126.8 to -90.91 Yes **** < 0.0001 C-J 
HCRA1_10 vs. 
HCRA2F1117A_50 
-92.11 -110.1 to -74.14 Yes **** < 0.0001 C-K 
HCRA1_10 vs. 
HCRA2F1117A_10 
-54.83 -72.80 to -36.86 Yes **** < 0.0001 C-L 
HCRA1Y1117A_250 vs. 
HCRA1Y1117A_50 
62.7 44.73 to 80.67 Yes **** < 0.0001 D-E 
HCRA1Y1117A_250 vs. 
HCRA1Y1117A_10 
91.04 73.07 to 109.0 Yes **** < 0.0001 D-F 
HCRA1Y1117A_250 vs. 
HCRA2_250 
-9.94 -27.91 to 8.027 No ns 0.797 D-G 
HCRA1Y1117A_250 vs. 
HCRA2_50 
61.02 43.06 to 78.99 Yes **** < 0.0001 D-H 
HCRA1Y1117A_250 vs. 
HCRA2_10 
91.61 73.65 to 109.6 Yes **** < 0.0001 D-I 
HCRA1Y1117A_250 vs. 
HCRA2F1117A_250 
-8.475 -26.44 to 9.491 No ns 0.9195 D-J 
HCRA1Y1117A_250 vs. 
HCRA2F1117A_50 
8.295 -9.671 to 26.26 No ns 0.93 D-K 
HCRA1Y1117A_250 vs. 
HCRA2F1117A_10 
45.57 27.61 to 63.54 Yes **** < 0.0001 D-L 
HCRA1Y1117A_50 vs. 
HCRA1Y1117A_10 
28.33 10.37 to 46.30 Yes **** < 0.0001 E-F 
HCRA1Y1117A_50 vs. 
HCRA2_250 
-72.64 -90.61 to -54.67 Yes **** < 0.0001 E-G 
HCRA1Y1117A_50 vs. 
HCRA2_50 
-1.677 -19.64 to 16.29 No ns > 0.9999 E-H 
HCRA1Y1117A_50 vs. 
HCRA2_10 
28.91 10.94 to 46.88 Yes **** < 0.0001 E-I 
HCRA1Y1117A_50 vs. 
HCRA2F1117A_250 
-71.18 -89.14 to -53.21 Yes **** < 0.0001 E-J 
HCRA1Y1117A_50 vs. 
HCRA2F1117A_50 
-54.41 -72.37 to -36.44 Yes **** < 0.0001 E-K 
HCRA1Y1117A_50 vs. 
HCRA2F1117A_10 
-17.13 -35.10 to 0.8380 No ns 0.0774 E-L 
HCRA1Y1117A_10 vs. 
HCRA2_250 
-101 -118.9 to -83.01 Yes **** < 0.0001 F-G 
HCRA1Y1117A_10 vs. 
HCRA2_50 
-30.01 -47.98 to -12.04 Yes **** < 0.0001 F-H 
HCRA1Y1117A_10 vs. 
HCRA2_10 
0.5767 -17.39 to 18.54 No ns > 0.9999 F-I 
HCRA1Y1117A_10 vs. 
HCRA2F1117A_250 
-99.51 -117.5 to -81.54 Yes **** < 0.0001 F-J 
HCRA1Y1117A_10 vs. 
HCRA2F1117A_50 
-82.74 -100.7 to -64.77 Yes **** < 0.0001 F-K 
HCRA1Y1117A_10 vs. 
HCRA2F1117A_10 
-45.46 -63.43 to -27.50 Yes **** < 0.0001 F-L 
HCRA2_250 vs. 
HCRA2_50 
70.96 53.00 to 88.93 Yes **** < 0.0001 G-H 
HCRA2_250 vs. 
HCRA2_10 
101.6 83.59 to 119.5 Yes **** < 0.0001 G-I 
HCRA2_250 vs. 
HCRA2F1117A_250 
1.465 -16.50 to 19.43 No ns > 0.9999 G-J 
HCRA2_250 vs. 
HCRA2F1117A_50 
18.24 0.2686 to 36.20 Yes * 0.0432 G-K 
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HCRA2_250 vs. 
HCRA2F1117A_10 
55.51 37.55 to 73.48 Yes **** < 0.0001 G-L 
HCRA2_50 vs. 
HCRA2_10 
30.59 12.62 to 48.55 Yes **** < 0.0001 H-I 
HCRA2_50 vs. 
HCRA2F1117A_250 
-69.5 -87.47 to -51.53 Yes **** < 0.0001 H-J 
HCRA2_50 vs. 
HCRA2F1117A_50 
-52.73 -70.70 to -34.76 Yes **** < 0.0001 H-K 
HCRA2_50 vs. 
HCRA2F1117A_10 
-15.45 -33.42 to 2.515 No ns 0.169 H-L 
HCRA2_10 vs. 
HCRA2F1117A_250 
-100.1 -118.1 to -82.12 Yes **** < 0.0001 I-J 
HCRA2_10 vs. 
HCRA2F1117A_50 
-83.32 -101.3 to -65.35 Yes **** < 0.0001 I-K 
HCRA2_10 vs. 
HCRA2F1117A_10 
-46.04 -64.01 to -28.07 Yes **** < 0.0001 I-L 
HCRA2F1117A_250 vs. 
HCRA2F1117A_50 
16.77 -1.196 to 34.74 No ns 0.0924 J-K 
HCRA2F1117A_250 vs. 
HCRA2F1117A_10 
54.05 36.08 to 72.01 Yes **** < 0.0001 J-L 
HCRA2F1117A_50 vs. 
HCRA2F1117A_10 
37.28 19.31 to 55.24 Yes **** < 0.0001 K-L 
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However, the differences in uptake could be negated by incubation of 
cells with high concentrations (1 µM) of both proteins (data not 
shown). Binding to neurons was dose dependent for all HCRs and HCR 
variants tested. When compared to parental HCRs, HCR/A1Y1117A and 
HCR/A2F1117A were able bind and enter neurons with higher efficiency, 
consistent with the in vitro binding assay (Figure 21 and statistical 
analysis on Table 7. HCR/A2F1117A was able to bind and enter cells 
more efficiently than all other proteins tested including HCR/A1, and 
HCR/A2. At increased doses however, the efficiency of entry is similar. 
 
3.5 Discussion and Future directions 
 
3.5.1 Discussion 
 Accumulating evidence suggests BoNT/A2 is more is more toxic 
and has higher relative activity than BoNT/A1. One reason for the 
higher toxicity of BoNT/A2 may be the higher efficiency of entry. 
BoNT/A2 has been shown to bind and enter both human and rodent 
derived neuronal cells with higher efficiency than BoNT/A1. Although 
highly conserved, BoNT/A1 and BoNT/A2 may not interact with the 
Sia5 sugar in the same manner. Stevens et al reported a structural 
discrepancy between the position of BoNT/A1Y1117 in the apostructure 
of BoNT/A1 and the BoNT/A1 HCR co-crystal with GT1b 
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oligosaccharide. In HCR co-crystal, Y1117 was rotated 25º and shifted 
1.7 Å in order to demonstrate ganglioside coordination with Sia5 as 
predicted in the apostructure. This work suggests BoNT/A1Y1117 and the 
equivalent residue, BoNT/A2F1117 are inhibitory to ganglioside binding 
and do not directly interact with the Sia5 sugar. Replacing the 
phenylalanine rings may allow the GA1 core to pack tighter against the 
conserved residues increasing affinity for ganglioside GT1b (Figure 
20). However, when HCR/A1Y1117A and HCR/A2F1117A were tested for 
relative affinity for GM1a, no binding was seen indicating suggesting 
Sia5 was still required.  
  Improving our understanding of the mechanism of BoNT/A1 and 
BoNT/A2 binding will enhance our overall understanding of the CNT 
entry and intoxication process. In addition, increased use of CNTs as 
therapeutics has caused development of antibody resistance.  
Development of a class of BoNTs with increased toxicity would lower 
the EC50 and decrease the chance of antibody mediated immune 
response.   
 
3.5.2 Future directions: Development of a heterologous 
reporter assay to assess the effects of point mutations on 
toxicity 
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 BoNTs are categorized as Tier 1 Category “A” Select Agents by 
the CDC. As a result, the production and use of recombinant, 
catalytically active toxin is highly regulated. It is therefore not practical 
to assess the effects of individual point mutations on toxicity in a 
catalytically active background.  Therefore, we decided to take 
advantage of the exclusion from Select Agent regulation of BoNT/A 
which contains three point mutations within the light chain that 
prevent zinc coordination, rendering the protein non-toxic [157]. 
Recently, βlac-TeNT(RY), a catalytic inactive variant of TeNT modified 
with an N-terminal β-lactamase reporter domain was utilized to 
measure LC translocation by detecting β-lactamase dependent 
cleavage of the FRET reporter substrate CCF2-AM [41]. Using 
catalytically inactive forms of BoNT/A1 and A2, β-lactamase reporter 
proteins (TEM-Bla_BoNT/A) were generated to test whether mutations 
which increase cellular uptake result in increased toxicity. After 
purification of recombinant toxins, an in vitro assay was carried out to 
verify the activity of β-lactamase utilizing the chromogenic 
cephalosporin nitrocefin (Sigma). The enzyme was found to be highly 
active, indicating expression and purification did not inhibit β-
lactamase function (Figure 22)  
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Figure 22. Validation of TEM_BLA reporter. An in vitro assay utilizing the 
chromogenic cephalosporin substrate nitrocefin. and 10 nm TEM BLA ciBoNT 
fusions showed high activity compared to nitrocefin controls and TEM BLA ciBoNT 
catalytic null. Data represents. Values represent the arithmetic mean± SD of 2 
independent experiments. 
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To assess TEM-Bla_BoNT/A1 and A2 function in cells, rat cortical 
neurons were incubated toxins for 3 hours to allow uptake and 
translocation, and then loaded with CCF4-AM. Cells were subsequently 
analyzed by flow cytometry to determine the ratio of green to blue 
cells. In theory, delivery of the lactamase into the neuronal cytosol will 
result in cleavage of CCF4, causing the cell to change color from green 
to blue. 
 Regrettably, under numerous experimental conditions, we have 
not yet been able to generate a population of cells with detectable 
translocated lactamase. We have consistently observed a pattern of 
green cells (75-80%) with a small population of double positive cells 
(4-10%) (Figure 23).  We have generated and increased a 
percentage of double positive cells, but as yet, have not detected a 
significant population of blue cells. It is unclear at this time whether 
the double positive cell population represents “noise”, or cells in which 
only a small percentage of the CCF4 substrate has been cleaved. While 
we are not currently able to explain why the assay is not working, one 
possible explanation might be linked to the localization of the BoNT/A 
LC within neurons. 
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Unstained CCF4 only 
ciBoNT A1 ciBoNT A2 
A. 
B. 
Figure 23. Heterologous LC Translocation Assay. (A) Untreated neurons or 
neurons exposed to CCF4-AM only. (B) Neurons treated with TEM-BLA A1 or TEM 
BLA A2 and exposed to CCF4 AM substrate were excited at 405 nm. Emission was 
taken at 455 nm and at 525 nm and 100,000 cells were counted. n=2 biological 
repeats. % distribution is shown. 
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 Previous work by Fernández-Salas and colleagues demonstrated 
that the LC of BoNT/A, but not BoNT/B or BoNT/E, is specifically 
localized to the plasma membrane [77, 158]. A subsequent study 
confirmed and extended these observations by showing that the LC of 
Tetanus toxin is also cytoplasmic [76]. Moreover, they demonstrated 
that removal of the first 8-17 N-terminal amino acids in LC/A resulted 
in loss of plasma membrane binding. The observation that Tetanus LC 
localizes to the cytoplasm while BoNT/A LC localizes to the membrane 
suggests this could alter the function of the lactamase. To test this 
possibility a construct lacking the first 10 amino acids was generated 
(TEM-Bla_BoNT/AΔ1-10). However, upon purification little or no full 
length product was isolated, suggesting the deletion may have 
destabilized the protein. An alternative to the Δ1-10 deletion construct 
is to mutate two lysine residues (K6 and K11) previously shown to be 
involved in membrane binding [76]. Given that the mutated LC/A 
protein has been previously expressed and purified from E. coli, we do 
not anticipate problems in the expression and purification of the 
mutated TEM-Bla_BoNT/A protein. If additional problems in expression 
and purification do arise and are not able to be resolved, the proteins 
could be expressed and purified from Bacillus megaterium, an 
alternative expression system used in the lab to express large proteins 
(>150 kDa) more effectively than E. coli. In the event that we are 
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unable to generate a functional reporter assay, catalytically active 
forms of the toxin will be assessed in the laboratory of Dr. Eric 
Johnson, University of Wisconsin, under Select Agent regulation. 
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CHAPTER 4: TETANUS NEUROTOXIN UTILIZES TWO 
SEQUENTIAL MEMBRANE INTERACTIONS FOR CHANNEL 
FORMATION 
 
As found in: Joshua R Burns and Michael Baldwin. Tetanus Neurotoxin Utilizes Two 
Sequential Membrane Interactions for Channel Formation. The Journal of Biological 
Chemistry. 2014;289(32):22450-22458.  
 
4.1 Abstract 
Tetanus neurotoxin (TeNT) causes neuroparalytic disease by entering 
the neuronal soma to block the release of neurotransmitters. Yet, the 
mechanism by which TeNT translocates its enzymatic domain (light 
chain, LC) across endosomal membranes remains unclear. We found 
that TeNT - and a truncated protein devoid of the receptor binding 
domain (TeNT-LHN) - associated with membranes enriched in acidic 
phospholipids in a pH-dependent manner. Thus, in contrast to diphtheria 
toxin the formation of a membrane-competent state of TeNT requires 
the membrane interface and is modulated by the bilayer composition. 
Channel formation is further enhanced by tethering of TeNT to the 
membrane through ganglioside co-receptors prior to acidification. Thus, 
TeNT channel formation can be resolved into two sequential steps: (1) 
interaction of the receptor binding domain (HCR) with ganglioside co-
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receptors to orient the translocation domain (HCT) as the lumen of the 
endosome is acidified and (2) low pH, in conjunction with acidic lipids 
within the membrane drives the conformational changes in TeNT 
necessary for channel formation. 
 
4.2 Introduction 
 Numerous bacterial pathogens produce toxins which enter into 
the cytosol of mammalian cells and disrupt normal cellular function. 
Many of these toxins are referred to as A-B toxins because of their 
structural and functional organization [159]. The B (binding) moiety, 
composed of one or more subunits, binds to a cell surface receptor and 
facilitates delivery of the A (active) moiety into the cytosol where it 
enzymatically modifies a cellular target. In a subset of A-B toxins, the 
B domain has the ability to undergo a series of structural changes that 
allows integration into lipid membranes and formation of a protein 
conducting channel through which the A domain may be delivered. 
What drives the structural changes within the B moiety and how 
polypeptides are translocated across membranes are fundamental 
questions yet to be fully resolved for any A-B toxin. 
 The clostridial neurotoxins (CNTs) are a family of bacterial A-B 
toxins which are among the most lethal natural agents known to 
humans [9, 160]. Nine CNTs have been described to date: tetanus 
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neurotoxin (TeNT) produced by Clostridium tetani, and eight botulinum 
neurotoxins (BoNTs, serotypes A-H) produced by strains of Clostridium 
botulinum, C. butyricum, and C. baratii [13, 136, 161, 162]. CNTs are 
synthesized as single chain polypeptides with a molecular mass of 
~150 kDa. The precursor is subsequently proteolytically cleaved into 
an ~50-kDa light chain (LC, A subunit) and an ~100 kDa heavy chain 
(HC, B subunit) linked by an essential interchain disulfide bond [26]. 
HC contains an ~50 kDa N-terminal translocation domain (HCT) and 
an ~50 kDa C-terminal receptor binding domain (HCR) [163]. The HCT 
facilitates translocation of the LC into the neuronal cytosol while the 
HCR binds neuronal co-receptors [54-56, 103, 153, 164-168]. 
How CNTs are able to convert from fully folded water-soluble proteins 
into membrane integrated protein translocating channels remains 
unclear. Traditionally low pH was proposed to trigger the translocation 
process, presumably by promoting structural changes facilitating the 
insertion of the HCT domain into the membrane bilayer. However, the 
recent demonstration that the isolated HCT domain of BoNT/A can 
form ion conducting channels in the absence of a transmembrane pH 
gradient brings this model into question [35, 60]. Rather, it appears 
that low pH serves to: (i) relieve the inhibition of the translocation 
process mediated by the HCR domain and (ii) facilitate the partial 
unfolding of the LC into a conformation necessary for passage through 
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the translocation channel [169, 170]. The presence of reductant and 
neutral pH in the cytosol promotes release of the LC from the HC after 
completion of translocation. While our understanding of the 
translocation process has grown in recent years, the precise molecular 
mechanisms driving the conversion of the water-soluble form into the 
membrane integrated form of TeNT remain to be determined. 
In the present study, we investigated mechanisms leading to 
formation of membrane channels using a combination of full-length 
TeNT and variants defective in the ability to bind ganglioside co-
receptors. Here we demonstrate that ganglioside binding enhances the 
rate of channel formation, presumably by tethering TeNT close to the 
target membrane. Furthermore, we demonstrate that membrane 
association is moderated by the presence of acidic phospholipids, 
suggesting the transition from a water-soluble protein into a 
translocase channel occurs close to the membrane interface. Based on 
our observations, we propose a sequential two-step model for TeNT 
channel formation that differs from the mechanisms employed by 
diphtheria and anthrax toxins, the current paradigms for cell entry of 
bacterial toxins. 
 
4.3 Experimental procedures 
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4.3.1 Reagents 
 Molecular biology grade reagents were purchased from either 
Fisher Scientific (Houston, TX) or Sigma-Aldrich Company (St. Louis, 
MO). Escherichia coli optimized DNA encoding TeNT residues 1-1315 
was synthesized by EZBiolab (Carmel, IN).  Gangliosides, cholesterol 
and the following phospholipids were purchased from Avanti Polar 
Lipids (Alabaster, AL): 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE), L-α-phosphatidylserine (Porcine brain), 
and L-α-phosphatidylcholine soy 20% (asolectin). 
 
4.3.2 Tetanus neurotoxin expression and purification 
 DNA encoding TeNT was cloned into the pET28a expression 
vector (Merck KGaA, Darmstadt, Germany) using appropriate 
restriction endonuclease sites resulting in an N-terminal His-tag fusion 
protein. To generate a catalytically inactive form of TeNT, two point 
mutations within the light chain (R372A and Y375F) were generated 
using the Quikchange II site-directed mutagenesis kit (Agilent). 
Proteins were expressed in E. coli BL-21 AI cells and purified as 
previously described [47, 111]. Peak fractions from the Sephacryl S-
200 column were concentrated using an Amicon filtration device (YM-
100 type filter), dialyzed into 10 mM HEPES-NaOH, 250 mM NaCl, pH 
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7.4 and stored at -80ºC until use. A typical preparation yielded 3-5 mg 
of purified toxin / liter of batch culture. 
 
4.3.3 Cloning and expression of TeNT LHN construct 
 DNA encoding TeNT amino acids 1-864 was amplified by PCR 
and cloned into the pET-28a expression vector using appropriate 
restriction endonuclease sites to generate an N-terminal His-tag fusion 
protein. Protein was expressed in E. coli BL-21 AI cells and purified as 
described for TeNT. 
 
4.3.4 Trypsinization of TeNT proteins 
 Trypsin agarose (500 µl) was washed three times in phosphate 
buffered saline (PBS) prior to incubation with 2 mg TeNT or TeNT 
variants for 60 min at 4ºC. Proteins were separated from agarose 
beads by gentle centrifugation and a sample resolved by SDS-PAGE. 
SDS-PAGE analysis of trypsinized proteins in the presence or absence 
of reducing agent confirmed the proteins were converted to di-chain 
molecules of the anticipated sizes (data not shown). 
 
4.3.5 Intoxication of rat cortical neurons with TeNT 
 Rat E18 cortical neurons (Brainbits, LLC, Springfield, Il) were 
cultured on poly-d-lysine coated glass coverslips in Neurobasal 
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medium supplemented with 0.5 mM Glutamax, Primocin, and B27 
supplement for 10−14 days prior to use. Cells were treated with TeNT 
or TeNT variants at the indicated concentrations for 24 hours at 37ºC. 
In some experiments, cells were pre-treated for 1 hour with either 100 
nM Bafilomycin A1 or solvent (DMSO) prior to addition of the toxins. 
Following treatment, cells were washed three times in Hanks balanced 
salt solution (HBSS), lysed with RIPA (radio immunoprecipitation 
assay) buffer at 4°C for 30 min and clarified by centrifugation at 
20,000×g. Lysates were boiled in SDS-PAGE sample buffer, resolved 
on 13.5% w/v SDS-PAGE gels, transferred to Immobilon PVDF 
membranes, and subjected to Western blotting using antibodies 
against VAMP2 (1:5000, clone 69.1, Synaptic Systems, Germany), 
beta-actin (1:1000, mAbcam 8226, Abcam, Cambridge, MA) and goat 
anti-mouse HRP (1:100,000, Pierce). The membranes were washed, 
incubated with SuperSignal Dura (Pierce), and visualized using a CCD 
imaging system. 
 
4.3.6 Circular dichroism 
 An AVIV model 202 far UV spectrometer was used to collect 
spectra (196 nm to 265 nm) of TeNT or TeNT variants (2 µM) obtained 
at pH 7.4 (10 mM HEPES-NaOH, 15 mM NaCl, 0.1 mM EDTA) and pH 
4.0 (10 mM sodium acetate-acetic acid, 15 mM NaCl, 0.1 mM EDTA) at 
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42ºC using 1 mm pathlength quartz cuvettes. Gangliosides were added 
to a final concentration of 30 µM unless otherwise indicated and 
samples were re-scanned. A spectrum of buffer alone or buffer + 
gangliosides were subtracted from the appropriate data sets. Data 
analysis was carried out using CDPro software [171]. 
 
4.3.7 Triton X-114 partitioning 
 Triton X-114 partitioning assays were performed as described 
previously [172]. For pH 7.4 samples, buffer containing 10 mM HEPES-
NaOH, 150 mM NaCl and 1 mM EDTA was used (hereafter referred to 
as neutral buffer). For samples at pH 6.5, 6.0, and 5.5, HEPES was 
replaced with 10 mM MES-NaOH and for pH 5.0 and 4.0, HEPES was 
replaced with 10 mM sodium acetate-acetic acid. Final concentrations 
were 600 nM for TeNT or TeNT variants and 113 µM ganglioside. After 
partitioning, the aqueous and detergent phases of each sample were 
collected and resolved on 8% w/v SDS-PAGE gels, visualized by silver 
staining and quantified by densitometry. 
 
4.3.8 Liposome preparation 
 Liposomes were freshly prepared by the freeze-thaw and 
extrusion method as described previously [173]. Briefly, lipids (40 
µmol total) dissolved in chloroform were mixed in the indicated ratios 
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(within Figure legends), dried under a gentle stream of nitrogen, and 
placed under vacuum overnight to remove residual solvent. The dried 
lipid cake was hydrated in potassium buffer (10 mM HEPES-KOH, 150 
mM KCl, 1 mM EDTA, pH 7.4) to a final concentration of 40 mM by 
brief sonication at 55ºC. The rehydrated lipid was then subjected to 
three cycles of rapid freeze-thaw, followed by extrusion through a 200 
nm pore membrane (Nucleopore) using a mini-extruder apparatus 
(Avanti Polar Lipids). Immediately prior to use, liposomes were 
exchanged into neutral buffer by passage over a pre-equilibrated 
column of G-25 sephadex. 
 
4.3.9 Association and proteoliposome isolation 
 Liposomes (100 µl) were combined with 10 µg TeNT or TeNT 
variants in 500 µl neutral buffer or low pH buffer (10 mM sodium 
acetate-acetic acid, 150 mM NaCl, 1 mM EDTA, pH 4.0). Liposomes 
were isolated by centrifugation at 100,000 ×g for 30 minutes at 4ºC. 
Supernatants containing unbound proteins were recovered and held on 
ice for further analysis. Liposomes were suspended in 500 µl fresh 
neutral or low pH buffer and recovered by centrifugation as above. 
Supernatants (Wash fractions) were collected, and along with those 
from the first centrifugation step, concentrated to ~50 µl using 
Microcon centrifugal filter devices. Liposomes were suspended in 50 µl 
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neutral buffer and all fractions mixed with an equal volume of SDS-
PAGE buffer. Volume equivalents of each fraction were resolved on 
SDS-PAGE gels and visualized by staining with Coomassie Blue dye. 
 
4.3.10 K+ Release assay 
 Liposomes (100 µl) were diluted into 5 ml neutral- or low pH- 
buffer with constant stirring and allowed to equilibrate for 1-5 minutes. 
TeNT or TeNT variants (2.5 nmol) were then added to the solution and 
potassium ion release monitored using a potassium selective electrode 
(Orion, ThermoFisher Scientific, Houston, TX). After 5 min 0.01 M KCl 
was added to the solution to ensure the electrode was functioning as 
expected. Specific K+ release was determined by subtraction of basal 
release values obtained from liposomes incubated in buffer alone. 
 
4.3.11 Statistical analysis 
 Densitometric analysis was performed using Protein Simple 
AlphaView 3.0 software (Santa Clara, CA). Data were analyzed using 
GraphPad Prism, version 6.0 (La Jolla, CA). One-way ANOVA with 
Student-Newman-Keuls post-test was performed to determine the 
difference between means after treatment. Two-way ANOVA with 
Bonferroni post-test was used to determine the difference between pH 
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and treatments and the possible interactions of each. Differences were 
considered significant at p < 0.05. 
 
4.4 Results 
 
4.4.1 Functional Entry of Recombinant Tetanus Toxin and 
Protein Variants into Cortical Neurons 
 The mechanism by which the LC protease of tetanus neurotoxin 
(TeNT) is translocated across the endosomal membrane is currently 
unresolved. To investigate this mechanism further, a series of TeNT 
variants were constructed (Figure 24A) and validated by monitoring 
their ability to enter primary cortical neurons. Exposure of neurons to 
recombinant TeNT resulted in efficient cleavage of the physiologic 
substrate VAMP2 after 24 hours as determined by Western blotting 
(Figure 24B). To determine whether the receptor binding domain of 
TeNT is essential for intoxication, a protein variant composed only of 
the LC and HCT domains was generated (Figure 24A).  
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Figure 24. TeNT cleavage of VAMP2 in rat cortical neurons. A, schematic 
representation of TeNT, ciTeNT, and TeNT-LHN showing domain organization. The 
disulfide bond between the LC and the HC in the mature toxin is indicated by S-S. B, 
rat cortical neurons (10–14 days in vitro) were incubated for 24 h with the indicated 
concentrations of TeNT (white bar), ciTeNT (gray bar), or TeNT-LHN (black bar). 
VAMP2 cleavage was visualized by Western blotting using a mouse α-VAMP2 
antibody, which recognizes only uncleaved VAMP2. VAMP2 levels were normalized to 
β-actin controls and then expressed as a percentage relative to untreated control 
cells ± S.E. (error bars) (≥3 individual experiments). C, rat cortical neurons were 
incubated for 1 h with either bafilomycin A1 or solvent (DMSO) prior to the addition 
of TeNT-LHN. VAMP2 cleavage was visualized and quantified as described above. 
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When applied to cells this variant, hereafter named TeNT-LHN, was 
able to enter cells and cleave VAMP2; however, a significantly higher 
concentration was needed relative to the full length toxin. Thus, similar 
to other A-B type toxins the receptor binding domain of TeNT is not 
essential for toxicity. Finally, a recombinant, full-length tetanus toxin 
was engineered with two point mutations within the light chain (R372A 
and Y375F). Arg372 and Tyr375 are conserved across all CNT family 
members and are known to contribute to catalysis by facilitating 
correct alignment of conserved histidine and glutamate residues for 
the Zn coordination sphere [78, 174, 175]. Treatment of cells with a 
10,000-fold higher concentration of the catalytic inactive form of toxin 
(termed ciTeNT) also failed to cleave VAMP2 (Figure 24B). This is 
consistent with the recent study of Blum et al [176] which showed that 
mice injected with 5 µg of a protein containing the same two 
mutations (R372A, Y375F, equivalent to ~125,000 lethal doses) did 
not develop any signs of disease. Thus, ciTeNT was substituted for wild 
type protein in the remaining assays to maximize safety. To further 
validate the use of TeNT-LHN as a tool to study translocation, the 
requirement for passage through an acidified compartment was 
investigated. In agreement with previous studies, the activity of 
recombinant TeNT was inhibited by the vacuolar proton pump inhibitor 
Bafilomycin A1 [177]. TeNT-LHN was also inhibited by Bafilomycin A1, 
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indicating that translocation of the light chain by TeNT-LHN was still 
dependent on exposure to an acidified environment (Figure 24C). 
 
4.4.2 TeNT Undergoes Secondary Structural Changes in the 
Presence of Polysialogangliosides at Low pH 
 Recent studies demonstrated that interaction of ganglioside 
GT1b with BoNT/B and BoNT/E triggers conformational changes within 
the two proteins that facilitates transformation into hydrophobic 
proteins at low pH [178, 179]. To test whether gangliosides trigger a 
similar conformational change in TeNT, CD spectroscopy was 
performed at neutral and acidic pH in the absence and presence of 
GT1b. At neutral pH, the far-UV CD spectra (196-265 nm) of TeNT 
with or without the addition of GT1b overlapped extensively and the 
helical content was estimated at 18.4% and 19.6% respectively 
(Figure 25A and Table 8). Reducing the pH to 4.0 had little effect on 
the CD spectrum of TeNT, indicating the protein secondary structure 
remains largely unchanged. By comparison, addition of GT1b at low pH 
caused a dramatic shift in the CD spectrum, with a reduction in helical 
content to 7.8% and a marked increase in beta-strand content to 
40.8%. The binding of several CNTs to gangliosides is mediated by a 
conserved binding pocket located within the receptor binding (HCR)  
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Figure 25. Polysialogangliosides induce changes in TeNT secondary 
structure at low pH. A, far-UV CD spectra of TeNT, TeNTRW, and TeNT-LHN at pH 
7.4 and 4.0 in the absence (solid lines) and presence (dashed lines) of 30 µm GT1b. 
B, far-UV CD spectra of TeNT at pH 4.0 in the absence (solid lines) or presence 
(dashed lines) of 1 µm GT1b, 30 µm GA1, or both. 
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Table 8. Far UV spectra values 
 
 
Secondary Structure 
pH 7.4 pH 4.0 
Toxin Buffer only Buffer + GT1b Buffer only Buffer + GT1b 
 % % % % 
TeNT α = 19.6 α = 18.4 α = 17.9 α = 7.8 
 β = 27.8 β = 27.9 β = 28.1 β = 40.8 
TeNTRW α = 21.6 α = 21.1 α = 19.5 α = 6.5 
 β = 25.6 β = 26.6 β = 27.9 β = 42.6 
TeNT-LHN α = 36.9 α = 34.3 α = 32 α = 5 
 β = 13.8 β = 14.5 β = 16.3 β = 45.7 
 
Secondary structure analysis of far UV CD spectra as determined by CD-PRO 
software for TeNT and TeNT variants at pH 7.4 and 4.0 
.  
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domain [47]. It was therefore anticipated that TeNT-LHN, which lacks 
the HCR domain, would not undergo secondary structural changes at 
low pH in the presence of ganglioside. However, similar to full length 
TeNT, TeNT-LHN shifted to a largely beta-strand dominated structure 
at low pH in the presence of ganglioside (Figure 25A and Table 8). It 
is therefore assumed that the conformational changes occurring in the 
LC and HCT domains of both proteins are largely the same. Finally, the 
CD spectra of a mutated TeNT protein deficient in the ability to bind 
gangliosides (previously termed TeNTRW) [103, 111] were acquired. 
The CD spectra of TeNTRW at both neutral and acidic pH are similar to 
those obtained with the wild-type protein (Figure 25 and Table 9). 
This is consistent with data indicating that mutations at R1226 and 
W1289 have little effect on the tertiary structure of the HCR domain 
[102]. Only by addition of GT1b at low pH could a change in the 
secondary structure of TeNTRW be observed (Figure 23A). Furthermore, 
pH-triggered conformational changes in TeNT could also be observed 
by addition of alternative polysialogangliosides - GD3, GM1a, GD1a 
and GD1b - previously demonstrated to bind TeNT in a HCR-dependent 
manner (data not shown, [111]). These data strongly argue against a 
role for the HCR domain in detecting the presence of gangliosides at 
low pH. Next, the assay was performed using GT1b at concentrations 
below the reported critical micelle concentration (CMC ~1×10-5M, 
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[180]). Under these conditions, addition of GT1b did not promote a 
shift in the CD spectrum of TeNT (Figure 25B). This implied that. 
structural changes in TeNT might simply be a function of ganglioside 
micelle formation If this assertion was correct, then it follows that 
micelles formed from asialo-GM1a (GA1) should also stimulate a 
change in TeNT secondary structure, However, as shown in Figure 
25B, addition of GA1 alone or as mixed micelles composed of GA1 and 
GT1b (30:1 molar ratio) did not result in secondary structure changes 
(Figure 25B). These observations suggest that both micelle formation 
and the presence of sialic acid(s) is necessary to drive conformational 
changes in TeNT at low pH. 
 
4.4.3 TeNT Partitions into the Detergent Phase in Triton X-114 
Partitioning Assays in the Presence of GT1b at Low pH 
 Triton X-114 phase partitioning is routinely exploited as a means 
of separating hydrophilic proteins from GPI-anchored-, acylated- and 
integral-membrane proteins [172]. Using this approach, the 
distribution of TeNT and TeNT-LHN between the aqueous and detergent 
phases in the presence or absence of ganglioside at pH values ranging 
from 4.0 to 7.4 was investigated. In the absence of GT1b, TeNT was 
largely recovered in the aqueous phase. However, the addition of  
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ganglioside caused TeNT to transition from the aqueous to detergent 
phase only as the pH decreased below ~6.5 (Figure 26A). In 
comparison, the partitioning of TeNT-LHN into the detergent phase was 
dependent on the addition of GT1b, but unaffected by the pH of the 
system (Figure 26B). This observation suggests the HCR domain may 
function in part to mask hydrophobic membrane binding regions until 
the toxin is exposed to a low pH environment. 
 
4.4.4 TeNT Associates with Liposomal Membranes Enriched in 
Acidic Lipids 
 The ability of TeNT to bind to liposomal membranes as a function 
of pH was determined. Consistent with the reported binding data, 
treatment of base liposomes (zwitterionic) with TeNT or TeNTRW at 
either neutral or low pH resulted in a minor release of total K+ content 
(Figure 27B and 27C). A similar level of release was also observed 
when base liposomes + PS (10 mol %) were exposed to TeNT or 
TeNTRW at neutral pH (Figure 27B). Initial experiments employing 
liposomes composed of zwitterionic lipids (base liposomes, PC: PE: 
Cholesterol, 45:45:10, mol %) did not result in detectable binding at 
either neutral or low pH (data not shown).  
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Figure 26. Gangliosides facilitate transformation of TeNT into a hydrophobic 
protein at low pH. Triton X-114 partitioning assays were performed at various pH 
values in the absence or presence of ganglioside. TeNT (A) and TeNT-LHN (B) were 
detected by silver staining, and the percentage distribution in the detergent phase 
was determined by densitometry. Mean values ± S.E. (error bars) for at least three 
independent experiments are shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
****, p < 0.0001, two-way analysis of variance with Bonferroni post-test. n.s., not 
significant. 
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Figure 27 TeNT associates with liposomal membranes. A, top, ~70 pmol of 
TeNT or TeNT-LHN was mixed with 4 µmol of asolectin liposomes in buffer at either 
pH 7.4 or pH 4.0. Proteoliposomes (Lipo.) were isolated by centrifugation, washed 
with buffer, and recovered by a second centrifugation step. Supernatants (Supt.) 
from the initial centrifugation step and wash fractions (Wash) were analyzed along 
with the proteoliposomes by SDS-PAGE. A representative example of TeNT and 
TeNT-LHN association with asolectin liposomes at pH 7.4 and pH 4.0 is shown. 
Bottom, the relative distribution of TeNT (white bars) and TeNT-LHN (black bars) ± 
S.E. (error bars) from three independent experiments was determined by 
densitometry. B, ~70 pmol of TeNT or TeNT-LHN was mixed with 4 µmol of base 
liposomes (45% phosphatidylcholine, 45% phosphatidylethanolamine, 10% 
cholesterol, mol %) containing increasing amounts of phosphatidylserine (0–40 
mol%) in buffer at pH 4.0. Proteoliposomes were isolated as above and resolved by 
SDS-PAGE, followed by staining with Coomassie Blue. The image is representative of 
at least three independent determinations. The relative distribution of TeNT (white 
bars) and TeNT-LHN (black bars) ± S.E. from the indicated number of independent 
experiments was determined by densitometry. 
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However, in agreement with previous studies [181, 182], pH 
dependent binding of both TeNT and TeNT-LHN to asolectin liposomes 
was observed (Figure 27A). Based on these opposing observations, it 
was postulated that the increased anionic charge present in asolectin 
liposomes might facilitate toxin binding. To directly examine this 
possibility, base liposomes containing increasing amounts of the acidic 
phospholipid, phosphatidylserine (PS) were prepared. As shown in 
Figure 27B, binding of TeNT to liposomes (base liposomes + PS) at 
low pH showed a clear dependence on PS through 40 mol %. This 
supports a role for acidic lipids in triggering membrane association of 
TeNT. While binding of TeNT-LHN to liposomes also showed a clear 
dependence on PS, association with base liposomes (no PS) was also 
increased relative to TeNT (Figure 27B). The reason for this 
difference is not yet clear, but may reflect exposure of hydrophobic 
surfaces by removal of the HCR domain. 
 
4.4.5 Acidic Lipids Enhance TeNT Mediated Release of K+ from 
Liposomes 
 To further characterize the role of acidic lipids in the action of 
TeNT, channel formation was assayed by measuring K+ release from 
liposomes at neutral and low pH using an ion specific electrode.  
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Addition of toxins to asolectin liposomes at low pH resulted in a rapid, 
dose dependent release of K+ content (Figure 28A). Treatment of 
liposomes with identical concentrations of toxins at neutral pH resulted 
in a small amount of K+ release (<5% of total K+ content, data not 
shown). Thus, it appears that a basal level of channel formation occurs 
in a manner largely independent of lipid composition. By comparison, 
when base liposomes + PS were exposed to TeNT or TeNTRW at low 
pH, a significant increase in the level of K+ release was observed, 
consistent with the model that membrane binding/ channel formation 
is enhanced by the presence of acidic lipids (Figure 28C). Given the 
observed increase in binding of TeNT-LHN to base liposomes (Figure 
25B) it was anticipated that this would also lead to increased K+ 
release at low pH. However, the K+ release evoked by TeNT-LHN was 
similar to that of TeNT and TeNTRW under the tested conditions 
(Figure 28B and 28C). Thus, at this time we are not able to explain 
the increased K+ release caused by TeNT-LHN from base liposomes 
containing 10 mol % PS versus base liposomes alone (Figure 28C). 
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Figure 28. Acidic phospholipids enhance K+ release from liposomes. A, 
asolectin liposomes (4 µmol) were diluted into buffer at pH 4.0 and incubated with 
the indicated proteins (2.5 nmol) for 5 min at 24 °C, and K+ release was recorded 
using an ion-specific electrode. K+ release values (mV) are the mean ± S.E. (error 
bars) of three independent experiments. Base liposomes (white bars) or base 
liposomes + PS (10% PS, mol %; black bars) were diluted into pH 7.4 (B) or pH 4.0 
buffer (C) and incubated with the indicated proteins for 5 min at 24 °C, and K+ 
release was recorded. K+ release values (mV) are the mean ± S.E. of three 
independent experiments. PC, phosphatidylcholine; PE, phosphatidylethanolamine. 
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4.4.6 Binding of TeNT to Liposomes Through Ganglioside 
Receptors Mediates Efficient Channel Formation 
 To determine what effect cellular receptors may play in the 
translocation process, base liposomes + PS were doped with  
gangliosides to facilitate direct binding of TeNT to the membrane. 
Initial experiments were conducted using liposomes containing 2 mol 
% GT1b and 10 mol % PS. Under these conditions the rate of K+ 
release was too rapid to allow for the contribution of GT1b to be 
assessed (data not shown). Therefore, the concentrations of PS and 
TeNT were reduced to the minimum levels necessary to detect K+ 
release as compared to base liposomes. Under these conditions (base 
liposomes + 2 mol % GT1b and 5 mol % PS) binding of TeNT - but not 
TeNTRW or TeNT-LHN was observed at both neutral and low pH (Figure 
29A). This demonstrates that binding of TeNT to liposomes containing 
gangliosides is mediated through HCR-ganglioside interactions, and 
not through electrostatic interactions between the toxin and the 
charged membrane environment. Coupling of the toxin to the 
liposomal membrane resulted in significantly enhanced release of K+ 
content when compared with base liposomes containing PS only.  
 
.  
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Figure 29 Ganglioside incorporation enhances K+ release from liposomes at 
low pH. A, ~70 pmol of TeNT was mixed with 4 µmol of base liposomes + PS and 
gangliosides (5% PS, 2% mixed gangliosides, mol %) in buffer at either pH 7.4 or pH 
4.0. Proteoliposomes were isolated by centrifugation, washed with buffer, and 
analyzed by SDS-PAGE followed by staining with Coomassie Blue. A representative 
example of TeNT association with liposomes at pH 7.4 and 4.0 is shown. B, base 
liposomes + PS (5% PS, mol %; white bars) or base liposomes + PS and 
gangliosides were diluted into buffer at pH 4.0 and incubated with the indicated 
proteins (1 nmol) for 5 min at 24 °C, and K+ release was recorded using an ion-
specific electrode. K+ release values (mV) are the mean ± S.E. of six independent 
experiments. Base liposomes + PS and gangliosides were p < 0.001 (***) or p < 
0.0001 (****) (one-way ANOVA with Student-Newman-Keuls post-test) compared 
with base liposomes + PS only. PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; n.s., not significant. 
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However, no such effect was observed when base liposomes + PS and 
gangliosides were incubated with either TeNTRW or TeNT-LHN (Figure 
29B). 
 
4.5 Discussion 
 Clostridial neurotoxins (CNTs) cause neuroparalytic diseases by 
preventing the release of neurotransmitters at nerve terminals In 
recent years our understanding of their structure- function 
relationships (e.g. catalytic light chain (LC), translocation (HCT), and 
receptor binding (HCR) domains), enzymatic mode of action, and 
identification of neuronal cell surface receptors have all rapidly evolved 
[163]. By comparison, the mechanism by which low pH drives the 
conversion of CNTs from water-soluble molecules into protein 
translocase channels remains elusive. Here we investigated the 
mechanism of channel formation by TeNT to gain new insights into this 
enigmatic step in the intoxication process. Our data are summarized in 
Figure 30, where we propose a novel two-step model for TeNT 
channel formation. Initially the HCR domain binds to ganglioside co-
receptors present in the neuronal plasma membrane (Step 1) [103, 
111].  
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Figure 30. Model for the pH-triggered membrane insertion pathway of 
tetanus neurotoxin. Initially TeNT exists as a fully folded, water-soluble protein 
freely able to diffuse within the extracellular milieu (TeNTsoluble form). Binding of TeNT 
to the plasma membrane is mediated by interaction of the HCR with ganglioside co-
receptors (Step 1). Ganglioside binding brings TeNT into close proximity to the target 
membrane and orients the catalytic LC and HCT domains for optimal channel 
formation and protein translocation. This interaction alone is not sufficient to initiate 
membrane insertion. Following endocytic uptake, protonation results in the formation 
of a membrane-competent state (indicated by the outlined diamond) at the 
membrane interface (TeNTinterfacial intermediate), which is regulated by lipid composition 
(Step 2). The intermediate state then rapidly transforms into the channel state able 
to mediate translocation of the enzymatic domain across the membrane. 
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This interaction presumably promotes partitioning into the bilayer by 
tethering the HCT domain close to the membrane, such that its 
orientation relative to the bilayer is optimal for subsequent channel 
formation. The interaction of HCR with ganglioside is independent of 
pH ranging from 4.0-7.4 (data not shown), suggesting the toxin 
remains bound to the membrane within the acidified endosome.  
Intriguingly, the interaction of BoNT/B with synaptotagmin II was also 
reported to be independent of pH, potentially signifying a shared 
mechanism among the CNTs [113]. The need to orient the HCT 
domain relative to the membrane may be related to the large α-helices 
of the domain which likely insert into the bilayer. By comparison, the 
interaction of diphtheria toxin with its cellular receptors is sensitive to 
pH, and consequently formation of membrane channels occurs 
independently of receptor [183]. Furthermore, CNTs do not undergo 
changes in secondary structure response to low pH alone (Figure 
23),as has been reported for diphtheria toxin [184]. Thus, the initial 
interaction of TeNT with the membrane does not appear to require the 
formation of a membrane-competent state in solution. In step 2, low 
pH triggers the formation of an interfacial intermediate state that is 
regulated by the presence of acidic lipids within the membrane. The 
molecular basis of this regulation is currently unknown and will be the 
subject of future investigations. The requirement for acidic lipids 
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further distinguishes TeNT from the interaction of diphtheria toxin with 
the bilayer which is largely unaltered by the physicochemical nature of 
the membrane. Once the toxin has formed the interfacial intermediate 
state, we posit a rapid and possibly irreversible transformation into the 
channel state occurs (Figure 30). Recent studies have demonstrated 
that BoNT/B and BoNT/E undergo pH-triggered conformational 
changes and transformation into oligomeric membrane proteins in the 
presence of ganglioside GT1b. We observed similar conformational 
changes in TeNT, a ganglioside-binding deficient form of TeNT 
(TeNTRW), and a truncated protein lacking the entire receptor binding 
domain (TeNT-LHN) at low pH in the presence of GT1b (Figure 25A). 
These data indicate that the observed structural changes in response 
to GT1b are not dependent on the HCR domain. Future studies are 
planned to determine if the HCR domains of BoNT/B and BoNT/E are 
necessary for the reported effects of ganglioside on secondary 
structure and oligomerization. How therefore is GT1b able to stimulate 
the observed changes in TeNT secondary structure? Based on the data 
presented in Figure 25 we hypothesize that the observed changes in 
secondary structure result from insertion of the HCT domain into the 
hydrophobic core of the ganglioside micelle. Moreover, given that 
addition of GA1 alone or GA1 in combination with a low amount of 
GT1b did not stimulate a change in secondary structure, the negative 
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charge of the sialic acids also appears to play an important role in the 
interaction. Thus it is posited that polysialoganglioside micelles mimic 
an acidic membrane environment necessary to drive the formation of 
the interfacial intermediate state as proposed in Figure 30. 
Low pH within the lumen of endosomal compartments has long been 
postulated as the trigger for translocase channel formation. This is in 
agreement with previous studies demonstrating single-channel activity 
of BoNTs in planar bilayers and membrane patches excised from 
neuroendocrine cell lines. Therefore what role if any, does lipid 
composition play in channel formation by BoNTs? Interestingly, 
channel formation in planar bilayer systems employed either asolectin 
or defined lipid mixtures containing both phosphatidylserine and 
ganglioside GT1b [42, 60]. Thus, the requirement for acidic lipids in 
regulating the formation of the TeNT interfacial intermediate state may 
be a shared property among the CNTs. Indeed, Fischer et al., 
previously noted that translocation activity of BoNT/A devoid of the 
receptor binding domain could not be observed in non-neuronal cell 
lines and speculated that membrane lipid composition might contribute 
to this effect [60]. 
 In summary, the data presented provide new insights into the 
mechanism by which the HCT domain is able to form a channel 
capable of translocating the LC moiety across the endosomal 
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membrane. Moreover, they suggest a new mechanism for A-B toxin 
translocation which differs significantly from the current paradigms of 
diphtheria and anthrax toxin. 
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CHAPTER 5: GENERAL DISCUSSION 
 
 Scientists and physicians have documented their study of 
botulism and tetanus since Hippocrates wrote of tetanus in the 5th 
century. With all that we have learned, we do not fully understand why 
BoNT is primarily retained in α-motor neurons and why TeNT is sorted 
into a retrograde axonal transport pathway. These studies focused on 
the contribution of the heavy chain receptor binding domain (HCR) to 
better understand mechanisms of ganglioside binding and receptor 
interactions required for toxicity, to better understand the difference 
between BoNT and TeNT. In addition, an investigation into the role of 
receptor binding and CNT translocation was carried out to better 
understand universal mechanisms of CNT pathogenesis. 
 One of the long term goals in CNT research has been to explain 
the unique ability of TeNT to interact with, or to associate with, 
detergent rich membranes (DRM) on the neuronal surface. GM1a was 
previously identified as a DRM marker, and has been shown to 
contribute to retrograde trafficking in cholera toxin and the E. coli heat 
labile toxins. To test the ability of TeNT to undergo retrograde axonal 
trafficking, a variant of HCR/T (HCR/TMO) required to bind Sia5 and 
unable to bind the DRM marker GM1a was developed. We propose the 
unique ability of TeNT to bind ganglioside GM1a allows TeNT to 
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undergo retrograde axonal trafficking. CNTs other than TeNT are able 
to bind multiple gangliosides. Analogous to TeNT, two ganglioside 
binding pockets have been identified in BoNT/C. However, structure 
based sequence alignments and the crystal structure of HCR/C 
demonstrate the mechanism of binding between HCR/C and TeNT are 
quite different. The Sia1 one site, composed of a distal loop and 
several non-connected peptides has high affinity for GT1b and low 
affinity for GM1a [185]. A second site, referred to as ganglioside 
binding pocket 2 (GBP2) has affinity for dia-sia sugars of b series 
gangliosides [168]. The ability to bind multiple gangliosides is not the 
only factor in retrograde trafficking. 
 As we did not test HCR/TMO in a direct retrograde trafficking 
assay, we cannot rule out a role for GM1 in retrograde axonal 
trafficking. In addition, we don’t know that HCR/TMO cannot be 
optimized. Identification of the determinant of TeNT retrograde 
trafficking, either a membrane raft domain or protein domain that 
directs TeNT entry into a retrograde pathway would be a significant 
finding and is worth continued effort. 
 Many variations in sequence and structure do not alter the 
function of the CNTs. Previous results suggest, as do prior data with 
HCR/T and HCR/TMO, the importance of characterizing individual CNT 
variants and subtypes. However, increasing data suggest seemingly 
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innocuous mutations may change serotype and subtype affinity for 
substrate or receptor. Thorough analysis of CNT serotypes and 
subtypes are required to better understand these mechanisms. For 
example, our lab previously published data demonstrating interactions 
between HCR/F and the Sia5 sugar are required for sufficient 
ganglioside binding and entry. Similar interactions are predicted to 
exist in HCR/A, but had not been tested biochemically.  
 A second study of receptor binding was undertaken utilizing 
ciBoNT/A1 and ciBoNT/A2. BoNT/A subtypes are 90% identical as 
determined by protein based sequence alignment. However, BoNT/A2 
was determined to be more toxic than BoNT/A1, and binding and entry 
more efficient as determined through biochemical and in vivo assays. 
Point mutations designed to test interactions between the Sia5 sugar 
and HCRs A1 and A2 indicated hydrogen bonds may not be present as 
indicated in the crystal structure of HCR/A1 and GT1b oligosaccharide. 
Mutation of F/Y-1117 to alanine increased affinity to ganglioside, 
suggesting a novel binding mechanism exists in BoNTs A1 and A2 that 
utilizes a conserved phenylalanine ring shared between HCR/A1 and 
A2. The presence of the phenylalanine ring may create torsion on GA1 
core sugars, preventing high affinity binding to core GBM residues. 
But, an interaction with Sia5 is still present as the toxin was unable to 
bind GM1a. Increased affinity for ganglioside in the absence of the 
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phenylalanine ring increased entry efficiency in cortical neurons and 
proteins had a higher ratio of colocalization with synaptophysin 
positive synaptic vesicles. A toxicity assay is currently under 
development in order to determine relative toxicity of induced 
mutations. 
 Discovery of a novel, shared entry mechanism, utilized by 
multiple BoNT serotypes opens the door to exciting therapeutic 
possibilities. Current BoNT treatments may have a limited treatment 
duration due to development of toxin antibodies. Developing BoNT/A2 
will improve our basic understanding of CNT binding and entry 
mechanisms which in turn will lead to development of improved 
treatment options and vaccine design. 
 The CNT intoxication process is a stepwise process that begins 
with binding and internalization at the neuronal membrane, followed 
by exposure to low pH, formation of a channel and LC translocation. 
CNT LC translocation is perhaps the least understood step of the 
intoxication process. LC translocation is shared between BoNTs and 
TeNT and is pH dependent. The CNTs are believed to form channels 
(via the HCT domain) in the vesicle membrane and cross from the low 
pH environment of the vesicle lumen into the neutral pH of the 
neuronal cytosol. One function of the low pH environment may be to 
regulate translocation. LC was shown to partially unfold at low pH, 
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prior to transiting the HCT channel. In addition to low pH, a new 
mechanism for HCT channel formation dependent on the presence of 
acidic lipids has been described [63]. In addition, the role for receptor 
binding in CNT channel formation, has been clarified. The presence of 
ganglioside in liposome membranes created a greater propensity for 
the toxin to insert and form ion selective channels. 
 The HCR domain may perform additional functions outside of 
receptor binding. It may serve as a pH sensor, preventing channel 
formation at neutral pH. In support of this idea, BoNT/A-HCT, lacking 
LC and HCR formed channels in a pH independent manner [186]. 
Similar to TeNT, ciBoNT was able to bind to acidic lipids at low pH 
suggesting a universal mechanism for interacting with acidic lipids at 
low pH although the mechanisms behind the process is not clear. 
 Full characterization of HCT/HCR interactions are required to 
understand the mechanism of CNT binding, entry, and channel 
formation leading to productive LC translocation. At best, we have an 
incomplete picture of the intoxication process. In order to better 
understand how the HCR contributes to channel formation, we need 
more complete understanding of how the structure is oriented on 
membrane and how it can therefore move. Static crystal structures are 
helpful, but do not provide all required information about fluid 
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membrane/protein interactions in order to understand how structural 
change occurs relative to membrane positioning.  
 This research has focused on mechanisms between toxin and 
host required for CNT toxicity in partial fulfillment of the Ph.D. 
requirements for the University of Missouri. 
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CHAPTER 6: APPENDIX 
 
 
Appendix 6.1  
 
 
Figure S1. Relative purity of TeNT and TeNT variants. 1 and 5 µg of TeNT and 
TeNT variants were analysed by SDS-PAGE and stained by Coomassie Blue. 
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Appendix 6.2 Chapter 2 primers 
 
HCR/T W1289A: 
Fwd: 
GATATTCTGATTGCGAGCAACGCGTATTTTAACCATCTGAAAGAT 
Rev: 
ATCTTTCAGATGGTTAAAATACGCGTTGCTCGCAATCAGAATATC 
 
R1226L 
Fwd: 
C AACCTGGATCGTATTCTGCTGCGTGTGGGCTATAACGCG 
Rev: 
CGCGTTATAGCCCACACGCAGCAGAATACGATCCAGGTT G 
 
HCR/T A1134L 
Fwd: 
GAATATTATCTGATTCCGGTGCTGAGCAGCAGCAAAGATGTGCAG 
Reverse: 
CTGCACATCTTTGCTGCTGCTCAGCACCGGAATCAGATAATATTC 
 
T1270F/H1271N 
Fwd: 
CGAGCCTGGGCCTGGTGGGCTTCAACAACGGCCAGATTGGCAACG 
Rev: 
CGTTGCCAATCTGGCCGTTGTTGAAGCCCACCAGGCCCAGGCTCG 
 
T1270F/H1271A 
Fwd: 
CG AGCCTGGGCCTGGTGGGCTTCGCGAACGGCCAGATTGGCAAC G 
Rev: 
CGTTGCCAATCTGGCCGTTCGCGAAGCCCACCAGGCCCAGGCTCG 
 
N1219S, R1226L 
Fwd: 
CCGAAAGATGGCAACGCGTTTAGCAACCTGGATCGTATTCTGCTG 
Rev: 
CAGCAGAATACGATCCAGGTTGCTAAACGCGTTGCCATCTTTCGG 
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N1219V, R1226L 
Fwd: 
CCGAAAGATGGCAACGCGTTTGTGAACCTGGATCGTATTCTGCTG 
Rev: 
CAGCAGAATACGATCCAGGTTCACAAACGCGTTGCCATCTTTCGG 
 
 
D1222E, R1226L 
Fwd: 
GGCAACGCGTTTAACAACCTGGAACGTATTCTGCTGGTGGGCTAT 
Rev: 
ATAGCCCACCAGCAGAATACGTTCCAGGTTGTTAAACGCGTTGCC 
 
D1222A/E, R1226L 
Fwd: 
GGCAACGCGTTTGCGAACCTGGAACGTATTCTGCTGGTGGGCTAT 
Rev: 
ATAGCCCACCAGCAGAATACGTTCCAGGTTCGCAAACGCGTTGCC 
 
T-MO: W/A 
Fwd: 
GATATTCTGATTGCGAGCAACGCGTATTTTAACCAGATCGAACGT 
Rev: 
ACGTTCGATCTGGTTAAAATACGCGTTGCTCGCAATCAGAATATC 
 
HCR/T-MO: R1299S 
Fwd: 
AACCAGATCGAACGTTCTTCTTCTACCCTGGGCTGCGATTGGTAT 
Rev: 
ATACCAATCGCAGCCCAGGGTAGAAGAAGAACGTTCGATCTGGTT 
 
D1222N 
Fwd: 
GGCAACGCGTTTAACAACCTGAACCGTATTCTGCGTGTGGGCTAT 
Rev: 
ATAGCCCACACGCAGAATACGGTTCAGGTTGTTAAACGCGTTGCC 
 
D1222A 
Fwd: 
GGCAACGCGTTTAACAACCTGGCGCGTATTCTGCGTGTGGGCTAT 
Rev: 
ATAGCCCACACGCAGAATACGCGCCAGGTTGTTAAACGCGTTGCC 
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G1300F 
Fwd: 
CCATCTGAAAGATAAAATTCTGTTTTGCGATTGGTATTTTGTGCCGACCG 
Rev: 
CGGTCGGCACAAAATACCAATCGCAAAACAGAATTTTATCTTTCAGATGG 
 
G1300Y: 
Fwd: 
CCATCTGAAAGATAAAATTCTGTATTGCGATTGGTATTTTGTGCCGACCG 
Rev: 
CGGTCGGCACAAAATACCAATCGCAATACAGAATTTTATCTTTCAGATGG 
 
R1226L/H1271A 
Fwd: 
CG AGCCTGGGCCTGGTGGGCACCGCGAACGGCCAGATTGGCAAC G 
Rev: 
CGTTGCCAATCTGGCCGTTCGCGGTGCCCACCAGGCCCAGGCTCG 
 
ARTS F-Loop/S1287A 
Fwd: 
CGTGATATTCTGATTGCGGCGAACTGGTATTTTAACAACATC 
Rev: 
GATGTTGTTAAAATACCAGTTCGCCGCAATCAGAATATCACG 
 
NART/H1271K 
Fwd: 
AGCCTGGGCCTGGTGGGCTTCAAAAACGGCCAGATTGGCAACGAT 
Rev: 
ATCGTTGCCAATCTGGCCGTTTTTGAAGCCCACCAGGCCCAGGCT 
 
R1226L/N1219A/H1271K 
Fwd: 
AGCCTGGGCCTGGTGGGCACCAAAAACGGCCAGATTGGCAACGAT 
Rev: 
ATCGTTGCCAATCTGGCCGTTTTTGGTGCCCACCAGGCCCAGGCT 
 
TeNT-BoNT/A Loop 
Fwd: 
CAGATCGAACGTTCTTCTCGTACCCTGGGCTGCGATTGGTATTTTGTG 
Rev: 
CAGGGTACGAGAAGAACGTTCGATCTGGTTAAAATACCAGTTGCTCGC 
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TeNT-BoNT/E Loop 
Fwd: 
CATATGCGTGATAACACCAACAGCAACGGCTGCGATTGGTATTTTGTGCCG
ACC 
Rev: 
GCCGTTGCTGTTGGTGTTATCACGCATATGGTTAAAATACCAGTTGCTCGCA
ATCAG 
 
 
TeNT-BoNT/F Loop 
Fwd: 
AACATCCGTAAAAACACCTCTTCTAACGGCTGCGATTGGTATTTTGTG 
Rev: 
GTTAGAAGAGGTGTTTTTACGGATGTTGTTAAAATACCAGTTGCT 
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6.3 HCR/TMO Manders Analysis 
	
Run	1	-	Mar	
2016	
	 	 	 	 	 	
	 	 	 	 	 	 	
Image	 Pearson'
s	
Coefficie
nt	
Manders	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
	 	 	 	 	 	 	
HCR/T_CTxB_37
_1	
0.739	 0.869	 0.924	 0.998	 0.972	 970967	
HCR/T_CTxB_37
_2	
0.782	 0.875	 0.946	 0.998	 0.883	 964651	
HCR/T_CTxB_37
_3	
0.751	 0.872	 0.938	 0.993	 0.981	 952751	
HCR/T_CTxB_37
_4	
0.805	 0.894	 0.939	 0.998	 0.934	 963450	
HCR/T_CTxB_37
_5	
794	 0.888	 0.969	 0.996	 0.902	 964605	
HCR/T_CTxB_37
_6	
0.806	 0.894	 0.94	 0.996	 0.984	 963445	
HCR/T_CTxB_37
_7	
0.758	 0.874	 0.942	 0.994	 0.976	 974993	
HCR/T_CTxB_37
_8	
0.767	 0.876	 0.963	 0.993	 0.977	 962732	
HCR/T_CTxB_37
_9	
0.789	 0.834	 0.947	 0.989	 0.976	 943788	
HCR/T_CTxB_37
_10	
0.731	 0.809	 0.959	 0.994	 0.977	 962458	
HCR/T_CTxB_37
_11	
0.759	 0.858	 0.962	 0.994	 0.974	 964590	
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HCR/T_CTxB_37
_12	
0.782	 0.869	 0.981	 0.994	 0.976	 960135	
HCR/T_CTxB_37
_13	
0.8	 0.912	 0.977	 0.993	 0.982	 969600	
HCR/T_CTxB_37
_14	
0.799	 0.871	 0.965	 0.996	 0.978	 970686	
HCR/T_CTxB_37
_15	
0.736	 0.794	 0.979	 0.995	 0.982	 962263	
	 	 	 	 	 	 	
Image	 Pearson'
s	
Coefficie
nt	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
	 	 	 	 	 	 	
HCR/T-
MO_CTxB_37_1	
0.556	 0.754	 0.906	 0.999	 0.767	 975315	
HCR/T-
MO_CTxB_37_2	
0.581	 0.698	 0.925	 0.997	 0.712	 968215	
HCR/T-
MO_CTxB_37_3	
0.421	 0.588	 0.967	 0.989	 0.653	 971289	
HCR/T-
MO_CTxB_37_4	
0.567	 0.764	 0.918	 0.994	 0.702	 969349	
HCR/T-
MO_CTxB_37_5	
0.46	 0.612	 0.968	 0.989	 0.688	 961192	
HCR/T-
MO_CTxB_37_6	
0.57	 0.772	 0.954	 0.992	 0.699	 962604	
HCR/T-
MO_CTxB_37_7	
0.57	 0.776	 0.968	 0.989	 0.705	 968018	
HCR/T-
MO_CTxB_37_8	
0.458	 0.597	 0.936	 0.986	 0.68	 965442	
HCR/T-
MO_CTxB_37_9	
0.506	 0.712	 0.967	 0.99	 0.718	 961932	
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HCR/T-
MO_CTxB_37_1
0	
0.438	 0.593	 0.994	 0.988	 0.628	 960438	
HCR/T-
MO_CTxB_37_1
1	
0.477	 0.635	 0.961	 0.992	 0.667	 968878	
HCR/T-
MO_CTxB_37_1
2	
0.552	 0.658	 0.985	 0.992	 0.678	 964721	
HCR/T-
MO_CTxB_37_1
3	
0.493	 0.606	 0.936	 0.986	 0.715	 968122	
HCR/T-
MO_CTxB_37_1
4	
0.507	 0.632	 0.923	 0.994	 0.725	 968404	
HCR/T-
MO_CTxB_37_1
5	
0.517	 0.628	 0.949	 0.989	 0.713	 969054	
	 	 	 	 	 	 	
Run	2	-	Apr	
2016	
	 	 	 	 	 	
	 	 	 	 	 	 	
Image	 Pearson'
s	
Coefficie
nt	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
HCR/T_CTxB_37
_1	
0.807	 0.91	 0.908	 0.994	 0.857	 899240	
HCR/T_CTxB_37
_2	
0.722	 0.814	 0.935	 0.996	 0.972	 904976	
HCR/T_CTxB_37
_3	
0.812	 0.915	 0.981	 0.994	 0.942	 900199	
HCR/T_CTxB_37
_4	
0.75	 0.845	 0.963	 0.984	 0.926	 904751	
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HCR/T_CTxB_37
_5	
0.681	 0.768	 0.924	 0.992	 0.907	 890711	
HCR/T_CTxB_37
_6	
0.736	 0.829	 0.975	 0.993	 0.956	 896605	
HCR/T_CTxB_37
_7	
0.814	 0.917	 0.883	 0.993	 0.847	 911852	
HCR/T_CTxB_37
_8	
0.71	 0.8	 0.903	 0.982	 0.818	 824047	
HCR/T_CTxB_37
_9	
0.749	 0.844	 0.915	 0.989	 0.832	 909320	
HCR/T_CTxB_37
_10	
	 	 	 	 	 	
	 	 	 	 	 	 	
Image	 Pearson'
s	
Coefficie
nt	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
HCR/T-
MO_CTxB_37_1	
0.611	 0.786	 0.903	 0.983	 0.723	 889886	
HCR/T-
MO_CTxB_37_2	
0.578	 0.744	 0.937	 0.993	 0.68	 891605	
HCR/T-
MO_CTxB_37_3	
0.503	 0.647	 0.918	 0.985	 0.741	 911903	
HCR/T-
MO_CTxB_37_4	
0.516	 0.664	 0.937	 0.988	 0.689	 900383	
HCR/T-
MO_CTxB_37_5	
0.621	 0.799	 0.936	 0.995	 0.688	 890364	
HCR/T-
MO_CTxB_37_6	
0.46	 0.591	 0.93	 0.997	 0.672	 894270	
HCR/T-
MO_CTxB_37_7	
0.448	 0.577	 0.915	 0.996	 0.707	 892152	
HCR/T-
MO_CTxB_37_8	
0.505	 0.65	 0.888	 0.991	 0.689	 907389	
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HCR/T-
MO_CTxB_37_9	
0.561	 0.721	 0.904	 0.989	 0.649	 896999	
HCR/T-
MO_CTxB_37_1
0	
0.475	 0.611	 0.955	 0.987	 0.666	 891520	
	 	 	 	 	 	 	
	 	 	 	 	 	 	
Image	 Pearson'
s	
Coefficie
nt	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
HCR/T_CTxB_4_
1	
0.833	 0.914	 0.979	 0.986	 0.967	 983368	
HCR/T_CTxB_4_
2	
0.731	 0.802	 0.956	 0.997	 0.929	 103411
0	
HCR/T_CTxB_4_
3	
0.809	 0.888	 0.923	 0.989	 0.974	 106432
7	
HCR/T_CTxB_4_
4	
0.744	 0.816	 0.925	 0.998	 0.935	 106322
6	
HCR/T_CTxB_4_
5	
0.847	 0.929	 0.965	 0.998	 0.935	 106480
0	
HCR/T_CTxB_4_
6	
0.802	 0.88	 0.97	 0.991	 0.949	 983457	
HCR/T_CTxB_4_
7	
0.818	 0.897	 0.938	 0.999	 0.972	 108311
1	
HCR/T_CTxB_4_
8	
0.812	 0.89	 0.949	 0.982	 0.982	 101848
6	
HCR/T_CTxB_4_
9	
0.743	 0.816	 0.975	 0.995	 0.969	 102907
7	
HCR/T_CTxB_4_
10	
765	 0.839	 0.986	 0.984	 0.946	 971387	
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Image	 Pearson'
s	
Coefficie
nt	
Overlap	
Coefficie
nt	
Ngree
n	/	
Nred	
Manders'	
coefficient_gr
een	
Manders'	
coefficient_
red	
Ntotal	
HCR/T-
MO_CTxB_4_1	
0.801	 0.879	 0.956	 0.991	 0.944	 102655
7	
HCR/T-
MO_CTxB_4_2	
0.787	 0.863	 0.977	 0.983	 0.978	 104810
8	
HCR/T-
MO_CTxB_4_3	
0.808	 0.886	 0.956	 0.99	 0.934	 107881
3	
HCR/T-
MO_CTxB_4_4	
0.785	 0.862	 0.943	 0.998	 0.963	 108218
5	
HCR/T-
MO_CTxB_4_5	
0.846	 0.928	 0.983	 0.991	 0.977	 108948
8	
HCR/T-
MO_CTxB_4_6	
0.765	 0.839	 0.95	 0.983	 0.927	 101215
2	
HCR/T-
MO_CTxB_4_7	
0.75	 0.823	 0.928	 0.984	 0.983	 901799	
HCR/T-
MO_CTxB_4_8	
0.825	 0.905	 0.971	 0.988	 0.959	 967397	
HCR/T-
MO_CTxB_4_9	
0.786	 0.844	 0.983	 0.922	 0.951	 952932	
HCR/T-
MO_CTxB_4_10	
0.739	 0.862	 0.977	 0.986	 0.94	 107025
5	
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